CURRICULUM VITAE - University of Wisconsin–Madison
JACQUES GALIPEAU MD FRCP(C)
Business address:
University of Wisconsin Carbone Comprehensive Cancer Center
Wisconsin Institute for Medical Research
1111 Highland Ave, Suite 3033
Madison, WI 53705-2275
Cell: 404-831-1209
Email: jgalipeau@wisc.edu
Citizenship: Canadian citizen & USA Permanent Resident
D.O.B: October 7th 1962
Civil Status: Married (Linda A. Smith), Children (Alexandra ‘91 & Max ‘94)
University Appointments:
• Assistant Dean for Therapeutics Discovery and Development, University of Wisconsin School of Medicine and Public Health (09/2016-current)
• Don and Marilyn Anderson Professor (Tenured) of Hematology & Medical Oncology, University of Wisconsin School of Medicine and Public Health (04/2017-current)
• Visiting Professor of Hematology & Medical Oncology, University of Wisconsin School of Medicine and Public Health (09/2016-04/2017)
• Professor of Hematology & Medical Oncology and Pediatrics, Emory School of Medicine (02/2010-09/2016)
• Visiting Professor of Hematology & Medical Oncology and Pediatrics, Emory School of Medicine (10/2009-02/2010)
• Associate Professor (with Tenure), Departments of Medicine and Oncology, McGill University (2004-2009)
• Assistant Professor, Departments of Medicine and Oncology, McGill University (1997-2004)
Hospital Appointments:
• Physician, UW Health (09/2016-current)
• Physician Member, Emory Clinic Inc. (10/2009-08/2016)
• Associate Professor, Division of Hematology/Oncology, Departments of Medicine and Oncology, Sir Mortimer B. Davis - Jewish General Hospital (2004-2009)
• Assistant Professor, Division of Hematology/Oncology, Departments of Medicine and Oncology, Sir Mortimer B. Davis - Jewish General Hospital (1997-2004)
Research & Program Appointments:
Director, UW Advanced Cell Therapy Program (09/2016-current)
Member, UW Stem Cell and Regenerative Medicine Center (10/2016-current)
Director, Emory Personalized Immunotherapy Center (EPIC) (02/2011-08/2016)
Member, Winship Cancer Institute (10/2009-08/2016)
Member, Emory Center for Transfusion and Cellular Therapies (10/2010-08/2016)
Emory University Ph.D. Program in Cancer Biology (CB) (10/2013-08/2016)
Emory University Ph.D. Program in Immunology & Microbiology (IMP) (10/2010-08/2016)
Project Director, Lady Davis Institute for Medical Research, McGill University (1997-2011)
Medical Director, Jewish General Hospital Cell Processing Center (2001-2009)
Theme Leader – Therapeutic applications, Canadian Stem Cell Network (National Center of Excellence) (2001-2009)
Education:
1995 – 1997: St-Jude Children’s Research Hospital, Memphis, TN. Post-Doctoral Fellowship in Gene therapy (Division of Experimental Hematology)
1992 – 1995: Tufts University, Boston, MA. Fellowship in Hematology-Oncology
(New England Medical Center Hospital)
1989 – 1992: McGill University, Montréal, Québec. Residency in Internal Medicine
(Sir Mortimer B. Davis Jewish General Hospital )
1988 – 1989: Université de Montréal, Montréal, Québec. Internship in Family Medicine
(Sacré-Coeur Hospital)
1983 – 1988: Université de Montréal, Faculty of Medicine (M.D. obtained 1988)
Certifications:
Certified Hematologist of the American Board of Internal Medicine 2010-2020. #146478
Diplomat of the American Board of Internal Medicine (Internal Medicine) 1992. #146478
Fellow of the Royal College of Physicians of Canada (Internal Medicine) 1993. #447373.
Specialist certificate (Internal Medicine) from the Collège des Médecins du Québec 1993. #13315
Specialist certificate (Haematology) from the Collège des Médecins du Québec 1995. #14019
Fellow of the Royal College of Physicians of Canada (Haematology) 1997.
Commissioned Officer in Her Majesty’s Canadian Armed Forces (1982) with Honorable Discharge at the rank of Captain (Infantry), Canadian Army Reserve (1991).
Licenses:
License of the Medical Council of Canada certificate of registration, #68991. Issued in 1989.
License for General Practice of Medicine in the Province of Ontario, #63255. Issued in 1990.
License for the Practice of Medicine in the Province of Québec, #93378. Issued in 1993.
License for the Practice of Medicine in the State of Georgia, # 63599. Issued in 2009.
License for the Practice of Medicine in the State of Wisconsin, #66345-20. Issued in 2016.
Academic Activities:
Journals
Invited reviewer:
Human Gene Therapy, Experimental Hematology, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, Cytotherapy, Gene Therapy, Journal of Gene Medicine, Stem Cells, Stem Cells Translational Medicine, Stem Cell Research, Cancer Immunology Immunotherapy, European Journal of Immunology, Journal of Neuroinflammation, Molecular Therapy, Stem Cell Reports, Clinical Cancer Research, American Journal of Transplantation, Cancer Research, Circulation, Blood, PNAS, JCI, Nature Biotechnology, Nature Communications, Nature Medicine and NEJM.
Grant Reviews and Panels
International Review Panels
• Invited expert reviewer for the 2017 Science Foundation of Ireland (SFI) SFI President of Ireland Future Research Leaders grant program. Dublin, Ireland February 2017
• Invited expert reviewer for the European Commission proposal evaluation campaign for Horizon 2020 research funding programme: Topic SC1-PM-11-2016-2017: Clinical research on regenerative medicine. Brussels, Belgium June 2016.
• Invited expert reviewer for the European Commission proposal evaluation campaign for Horizon 2020 research funding programme: Topic PHC-15-2015: Clinical research on regenerative medicine. Brussels, Belgium April 2015.
• Invited reviewer for the 2013 edition of translational research program in health (PRTS) proposed by the General Directorate for Cares (DGOS, French Ministry of Health) and the Agence Nationale de la Recherche (ANR) July 2013.
• Invited reviewer for Leukemia & Lymphoma Research (United Kingdom) September 2013.
• Invited reviewer for Netherlands ZonMW Translationeel Adult Stamcelonderzoek Call 3e ronde 2013 [Translational Adult Stem Cell Research] May 2013
National Cancer Institute (NCI)/National Institutes of Health (NIH)
• Invited Panel Member P01 Special Emphasis Panel III on Cell-Mediated Clinical Oncology Studies: June 2009, October 2009, February 2010, October 2010, June 2011, January 2012, June 2012, October 2014, June 2015.
• Invited Panel Member NCI R03/R21 Special Emphasis Panel (SEP) “Drug Development and Discovery”, November 2013, March 2016.
• Invited Panel Member NCI U24 Special Emphasis Panel (SEP) “Cancer Immune Monitoring and Analysis Centers (CIMACs)”, July 2017.
National Cancer Institute of Canada (NCIC)
NCIC Terry Fox Project Program Grant Site visit team, Toronto November 2002
Fonds de recherche en santé du Québec (FRSQ)
Chair, CFI/FRSQ New Investigator Awards December 2001; Invited Panel member, CFI/FRSQ New Investigator Awards, January 2004, September 2004; Chair, review committee for FRSQ réseau en médecine génétique appliquée, February 2004
Canadian Institutes for Health Research (CIHR)
Invited Panel member, MRC Cancer B review committee (04/1998), Panel Member CIHR Cancer B review committee (09/2000 to 06/2003); Invited Chair CIHR Cancer B review committee 05/2002 & 12/2002; Invited Panel member, CIHR Experimental Medicine, December 2003; Invited Panel Member, CIHR Cardiovascular System B (CSB) May 2005; Panel Member, CIHR Cardiovascular System B (CSB) July 2005-June 2007; Invited Scientific Officer, CIHR Cardiovascular System B (CSB) December 2006; Invited Chair, CIHR Cardiovascular B (CSB) May 2007, June 2008.
National review panels (Canada)
Invited Panel member for the Ontario Cancer Research Network, January 2002, June 2004; Invited expert on stem cells at the Conférence citoyenne publique et l’homme créa la génomique. February 5th 2005, Centre des Sciences de Montréal, Groupe de recherche en bioéthique de l’université de Montréal; Member of the Canada Research Chairs Program College of Reviewers (Nov 2006 – current); Member of Expert Committee for Canada Foundation for Innovation Jan 5 2009.
Invited peer reviewer for other Canadian granting agencies
Canadian Blood Services, Bayer Partnership Fund, Canadian Heart and Stroke Foundation, Canadian Cancer Etiology Network, Canadian Kidney Foundation, The Hospital for Sick Children Foundation, Canadian Foundation for Innovation, Canadian Liver Foundation, Canadian Gene Cure Foundation and National Sciences and Engineering Research Council of Canada (NSERC).
University Standing Committees
Appointed Faculty Representative for the School of Medicine, Emory University Faculty Council (08/2015-current)
Member Elect, Emory School of Medicine Faculty Relations Committee (06/2014-06/2017)
Member, Research Advisory Committee of the Emory University School of Medicine (09/2010 - current)
Member, Embryonic Stem Cell Research Oversight Committee of the Emory University School of Medicine (10/2010 - current)
Member, Core Oversight Committee of the Emory School of Medicine (09/01/11 – 09/2013)
Member, Research Ethics Board - Sir Mortimer B. Davis Jewish General Hospital (1998-2004) and Associate Chair (2001-2004)
Member, Équipe multidisciplinaire du Programme de la Maladie de Gaucher du Québec (2000-2009)
Member, Scientific Committee for the Leukemia Cell Bank of Quebec (2003-2009)
Scientific Committees and Boards
• External Consultant for the Intestinal Stem Cell Consortium (ISCC) (2016-current)
• Co-Chair, International Society of Cell Therapy Working Group on Mesenchymal & Tissue Stem Cells (December 2015 – current)
• Committee Member, International Society of Cell Therapy Working Group on Mesenchymal & Tissue Stem Cells (October 2005 – current)
• Member, Board of Directors, Canadian Stem Cell Network (2012 – current)
• Member, Cell and Tissue Advisory Committee for Héma-Québec Comité consultatif sur la production cellulaire et tissulaire « CCPCT ». (2012 – current)
• Member, External Advisory Board, Canadian National Transplant Research Program (2012 – current)
• Foundation for the Accreditation of Cellular Therapy (FACT) Regenerative Medicine Task Force (2014 – current)
Scientific Meetings organization and Chairs
• Abstract reviewer for the International Society for Stem Cell Research (ISSCR) Congress 2017 Meeting, Boston, MA.
• Abstract reviewer for the European Bone Marrow Transplantation Society: EBMT Congress 2017 Meeting, Marseille, France.
• Member of the organizational Committee for the 22nd annual meeting of the ISCT [International Society for Cell Therapy] 2016 congress to be held in Singapore, May 2016.
• Co-Chair of the Organizational Committee for the 21st annual meeting of the ISCT [International Society for Cell Therapy] 2015 congress held in Las Vegas, May 2015.
• Abstract reviewer for the European Bone Marrow Transplantation Society: EBMT Congress 2015 Meeting, Istanbul, Turkey.
• Member of the organizational Committee for the 20th annual meeting of the ISCT [International Society for Cell Therapy] 2014 congress held in Paris, April 2014.
• Abstract reviewer for the European Bone Marrow Transplantation Society: EBMT Congress 2014 Meeting, Milan, IT.
• Chair, Workshop on “Mesenchymal Stromal Cells: Universal Donor for Cell Therapy” at the 14th Annual International Society of Cell Therapy Meeting May 2008 (Miami, FL)
• Chair, Oral abstracts presentations “Mesenchymal & Tissue Stem Cells 2” at the 13th Annual Meeting of the International Society for Cellular Therapy in Sydney, Australia June 2007
• Co-organizer for the Quebec-New Jersey Stem Cell Workshop, held at McGill University June 4-5 2007 (45 participants)
• Chair, Scientific Simultaneous Session on “Stem Cell Niches – Osteoblasts and Other Cells” at the 46th American Society of Hematology Meeting 2004 (San Diego, CA)
• Head of the organizational committee for the Montreal Center for Experimental Therapeutics 2nd Colloquium in Cancer Gene Therapy, held at the NRC Biotechnology Research Institute, 10-11 April 2002 (125 participants).
• Head of the organizational committee for the Montreal Center for Experimental Therapeutics 1st Colloquium in Cancer Gene Therapy, held at the Université de Montreal School of Veterinary Medicine, 27 November 2001 (75 participants).
• Member of the organizational Committee for the 3rd Canadian Gene Therapy Symposium (Montreal, 1998)
Professional and Learned Societies
Founding Member of the Quebec Gene Therapy Association (Secretary 1998-2001)
Member, American Society of Hematology (ASH)
Member, International Society for Cell Therapy (ISCT)
Member, International Society for Stem Cell Research (ISSCR)
Fellow, Royal College of Physicians of Canada
Member, American Association of Immunologists (AAI)
Member, American Society of Transplantation (AST)
Member, Society for Immunotherapy of Cancer (SITC)
Awards and Scholarships:
CRSNG undergraduate summer research grant #122626 (1983)
1994 Detweiler Travelling Fellowship from the Royal College of Physicians of Canada
1994 Research Fellowship from the Canadian Heart and Stroke Foundation (Award declined)
1994-2000 Medical Research Council of Canada Clinician-Scientist Award Phase I
• 2000-2006 Medical Research Council of Canada Clinician-Scientist Award Phase II
• 2000-2003 Fonds de Recherche en santé du Québec Chercheur-Boursier Niveau I
• 2004 Sir Mortimer B. Davis Jewish General Hospital « Excellence in Research » Prize
• 2006-2010 Fonds de la recherche en santé du Québec chercheur-boursier sénior
• 2009-2016 GRA Distinguished Cancer Scientist
Research Activities:
My laboratory research is focused on cell and biological therapy of cancer and immune ailments. We are also exploring the utility of mesenchymal stromal cells for regenerative medicine, immune modulation and for delivery of therapeutic proteins for treatment of acquired and hereditary diseases.
Ongoing Research Support
Principal Investigator, 2.4 months, Inducible B-regulatory cells (iBREGs) for treatment of Multiple Sclerosis, NIH/NIAID, 1R01AI093881, 12/1/2011−11/30/2017(NCE), $1,937,500 ($387,500/year)
Principal Investigator, 2.4 months, Cytokine primed autologous Mesenchymal Stromal Cells for therapy of colitis, NIH/NIDDK, 1R01DK109508, 05/1/2016−04/30/2020, $2,091,796 ($522,949/year)
Investigator, 2.4 months, Development of GIFT4: A B-cell focused Immunotherapy for Cancer The goal of this program is to develop GIFT4 recombinant protein for cancer immunotherapy. NIH/NCI R44CA217365 (PI: Guyre) 05/12/2017-04/30/2019
Food and Drug Administration (FDA) Investigational New Drug (IND) Sponsorship
Sponsor-Investigator, IND #14825: “Autologous bone marrow derived Mesenchymal Stromal Cells for Crohn’s disease”. Issued: March 6th 2012. In support of clinical trial: NCT01659762
Sponsor-Investigator, IND #16191: “A Phase I Study of Autologous Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft versus Host Disease”. Issued: October 31st 2014. In support of clinical trial NCT02359929
Sponsor-Investigator, IND #16872: “A Phase I Autologous Mesenchymal Stromal Cells for severe sickle cell disease undergoing haploidentical hematopoietic cell transplantation”. Issued: June 23rd 2016.
Past Research Support
1. 1998-1999 Leukemia Research Fund of Canada operating grant $30,000 per year (successful renewal obtained in 09/1999 was declined due to duplicate grant from Cancer Research Society)
2. 1998-2000 Medical Research Council of Canada operating grant MA-15017 $65,000 per year
• 1999-2001 Cancer Research Society operating grant Gene therapy of Graft versus host Disease $50,000 per year. Principal Investigator: J. Galipeau, co-applicant: Clément Couture.
• 2001 Medical Research Council equipment grant MMA-43805 Pseudotyped Retrovectors for cell and gene therapy of cancer. $26,446. Principal Investigator: J. Galipeau.
• 2000-2002 Fonds d’établissement pour jeunes chercheurs du FRSQ $15,000 per year for two years
• 2001-2003 Stem Cell Network – Center of Excellence (StemNet). Human drug resistance genes for dominant selection of genetically-engineered hematopoietic stem cells. $40,000 per year. Principal Investigator: J. Galipeau, co-applicant: R. Momparler
• 2001-2003 Canadian Heart and Stroke Foundation. Therapeutic angiogenesis by autologous marrow stromal cells genetically-engineered to secrete erythropoietin. $12,000 per year for two years. Principal Investigator: J. Galipeau, co-applicant: K. Lachapelle
• Wyeth-Ayerst Canada and CIHR Rx&D Research Program Post-Graduate Fellowship Program 2002. Salary for a post-doctoral Fellow 2002-2003
• 2000-2003 Medical Research Council Clinician-Scientist Scholarship Phase II – Operating funds $40,000 per year for 3 years. Principal Investigator: J. Galipeau.
• 2001-2003 Cancer Research Society operating grant. Gene therapy of Graft versus host Disease $56,000 per year. Principal Investigator: J. Galipeau, co-applicant: Clément Couture.
• 2000-2003 Medical Research Council operating grant Identification of novel gene involved in T-cell activation by insertional mutagenesis– $70,000 per year. Principal Investigator Clément Couture, Co-applicant: J. Galipeau.
• 2000-2003 NCIC Terry Fox New Frontiers operating grant Cancer gene therapy: A comprehensive multi-pronged strategy for growth factor targeting. $246,000 year one, $218,000 years two and three. Principal Investigator: Pnina Brodt (McGill University), Co-investigators: Bernard Massie and J. Galipeau.
• 2001-2003 Bayer/Canadian Blood Services/Hema-Quebec Partnership Fund. Cell therapy of Hemophilia B. $80,000 per year. Principal Investigator M. Blostein, co-applicant: J. Galipeau.
• 2002-2004 Anemia Institute for Research and Education Operating Grant. Autologous bone marrow stromal cells genetically-engineered to secrete erythropoietin for anemia therapy $30,000 per year for two years. Principal Investigator: J. Galipeau
• 2000-2004 Medical Research Council operating grant MA-15017 Pseudotyped Retrovectors for cell and gene therapy of cancer. $93,000/yr for 4 years. Principal Investigator: J. Galipeau
• 2001-2004 CIHR Strategic Initiative Grant – Gene Therapy for Neurological Disease ($1,500,000 total over three years). Principle Investigator: G. Karpati, 25 co-applicants including J. Galipeau. $16,000 per year per investigator.
• 2001-2004 Valorisation Recherches Québec – Montreal Center for Experimental Therapeutics in Cancer ($2,700,000 over four years). Principle Investigator G. Batist. Co-applicant J. Galipeau $60,000 per year.
• 2003-2005 Stem Cell Network – Center of Excellence (StemNet). Evaluation of Genetically-modified, Autologous adult stem cell populations for the treatment of Hemophilia A. $57,500 per year to: J. Galipeau, co-applicant. Principal Investigator: D. Lillicrap.
• 2003-2005 US ARMY Concept Award. Mesenchymal Stem Cells for Vascular Target Discovery in Breast Cancer-Associated Angiogenesis. Log No. BC023590. $US80,000. Principal Investigator J. Galipeau
• 2003-2005 US ARMY Concept Award. Soluble Erythropoietin Receptor for Gene Therapy of Breast Cancer. Log No. BC0023328. $US80,000. Co-applicant J. Galipeau. (Principal applicant is Dr. N. Eliopoulos, a PDF in Galipeau laboratory)
• 2004-2006 Bayer Hemophilia Award. Genetically Modified Autologous Blood and Marrow-derived Stem Cells for the Treatment of Hemophilia A. $180,000USD over 2 years. Principal Investigator: J. Galipeau. co-applicant: D. Lillicrap (Queen’s University)
• 2004-2005 Anemia Institute for Research and Education Operating Grant. Autologous bone marrow stromal cells genetically-engineered to secrete erythropoietin for anemia therapy in patients with end-stage renal disease $30,000. Principal Investigator: J. Galipeau
• 2003-2005 Canadian Heart and Stroke Foundation. Defining the vascular plasticity of marrow stromal cells for the purpose of therapeutic neovascularisation. $17,000 per year for two years. Principal Investigator: J. Galipeau, co-applicant: K. Lachapelle.
• 2004-2007 Programme Hémovigilance FRSQ Regroupement stratégique québécois pour la recherche et le développement de la thérapie cellulaire et génique pour les maladies hémovasculaires. $673,205 over 3 years. Principal Investigator : J. Galipeau
• 2005-2008 Stem Cell Network – Center of Excellence (StemNet). Stem cell-based gene therapy for hemophilia A. $71,200 per year for 3 years to J. Galipeau, co-applicant. Principal Investigator: D. Lillicrap (Sept 1, 2005 to Sept 1, 2008).
• 2005-2008 Stem Cell Network – Core ¨Project Proposal 2005: CARE-NeT- SCN partnership: a focus on clinical translation of stem cells for cardiovascular regeneration. $89,000 over 3 years. Principal Investigator: J. Galipeau
• 2007-2008 CIHR Proof-of-Principle Program. The Ex Vivo Generation of Suppressive Cells for The Treatment of Multiple Sclerosis. $150,000. Principal Investigator: J. Galipeau
• 2004-2009 Canadian Institutes for Health Research (CIHR). Cancer cell and gene therapy - A study of novel chimeric anticancer immunomodulatory transgenes and transgenic cell therapy. $693,170 over 5 years. Principal Investigator: J. Galipeau
• 2004-2009 Regenerative Medicine and Nanomedicine: Innovative Approaches in Health Research - New Emerging Team Grant Program. (CIHR RMF 72553). Cardiovascular and Respiratory Stem Cell Plasticity – CARE project. $1,500,000 over 5 years. Principal Investigator: J. Galipeau
• 2008-2009 Canadian Gene Cure Foundation. Use of bone Marrow Stromal Cells for treatment of neuronopathic Gaucher disease. $65,000. Principal Investigator: J. Galipeau.
• 2007-2010 Programme Hémovigilance FRSQ Regroupement stratégique québécois pour la recherche et le développement de la thérapie cellulaire et génique pour les maladies hémovasculaires. $900,000 over 3 years. Principal Investigator: J. Galipeau
• 2007-2010 TFF New Frontiers Program Project Grant. Activated B cells and mesenchymal stromal cells as breast cancer vaccine platforms. $315,576 over 3 years. Co principal investigators: Dr. J. Galipeau and Dr. D. Spaner.
• 2008-2010 Stem Cell Network – Center of Excellence (StemNet). Stem cell-based gene therapy for hemophilia A. $120,000 over 2 years to J. Galipeau, co-applicant. Principal Investigator: D. Lillicrap (Oct 1, 2008 to Sept 30, 2010).
• 2007-2010 Roche Foundation for Anemia Research - RoFAR Cell and Gene Therapy with Erythropoietin-Secreting Marrow Stem Cells for Kidney Repair. $750,000 over 3 years. Principal Investigator: Dr. N. Eliopoulos and J. Galipeau (co-applicant).
• 2008-2010 Stem Cell Network – Core ¨Project Proposal 2005: CARE-NeT- SCN partnership: a focus on clinical translation of stem cells for cardiovascular regeneration. $666,000 over 2 years. Principal Investigator: J. Galipeau
• 2009-2011 Canadian Institutes for Health Research (CIHR). Cancer cell and gene therapy - A study of novel chimeric anticancer immunomodulatory transgenes and transgenic cell therapy. $460,000 over 2 years. Principal Investigator: J. Galipeau
• Principal Investigator, 0.12 months, Novel Fusokine for Expansion and Activation of IL7R+Lymphoid Cells for HIV. NIH/NIAID P30 AI050409: CFAR03 2011A, 07/1/2011-06/30/2012 $86,613
• Co- Principal Investigator with Edmund K. Waller at Emory University Winship Cancer Institute, 0 months, Cancer Immunotherapy Trials Network (CITN) Subcontract Site: Emory University will participate in the design and performance of novel early phase cancer immunotherapy clinical trials. NIH/NCI 1U01CA154967-01 Cheever (PI), 01/01/2011-09/30/2015
• Investigator, 0.12 months, A Phase I Clinical Trial of Autologous Mesenchymal Stromal Cells in Crohn’s Disease. CCFA Senior Research Award Reference # 253600 (Subra Kugathasan; PI) 01/08/2013-01/08/2015 ($115,830/year)
• Investigator, 0.12 months. Mesenchymal Stem Cell Therapy for Active Systemic Lupus Erythematosus. NIH 1R34AI114453 Gilkeson (PI), 12/01/2014-11/30/15 ($150,000/year)
• Principal Investigator. MyBregs LLC Georgia Research Alliance Venture Lab Award GRAVL15C12, 01/15/2015-01/15/2016 ($70,470/year)
• Investigator, 0.6 months. Adjuvants for skin immunization: Discovery and mechanisms. NIH/NIAID 1R01AI111557 Skountzou (PI), 08/05/2014-07/31/2016 ($577,659/year)
• Investigator, 0.4 months. ITN Study No.: ITN062ST: Atembtuzumab, Costimulation Blockade and Sirolimus: A Tolerogenic Canvas for Donor Antigen Delivery via Mesenchymal Stem Cells. Kirk (PI) NIH NIAID UM1AI109565 Immune Tolerance Network 10/01/2014-12/31/16 ($90,000 subaward)
• Investigator, 0.6 months. Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation. NIH/NCI 1R01CA188523 Waller (PI) 03/01/14-08/31/2016 ($207,500/year)
• Investigator, 0.2 months. Effects of reprogrammed and engineered MSCs on diabetic complications. NIH/NIDDK 1DP3DK108245-01 Yoon (PI) 09/30/15-08/31/2016 (total funding $2,424,957)
• Principal Investigator, 3.84 months, Cancer cell and gene therapy - A study of novel chimeric anticancer immunomodulatory transgenes and transgenic cell therapy. Georgia Cancer Coalition Distinguished Cancer Scholar. 07/01/09-6/30/16, $750,000 ($150,000/year)
Patents Issued:
1. STROMAL ANTIGEN PRESENTING CELLS AND USES THEREOF. U.S Patent #7,553,661 issued June 30, 2009. Inventors: Galipeau J. and Stagg J.
2. FUSION PROTEINS AND METHODS FOR MODULATION OF IMMUNE RESPONSE. U.S. Patent #7,947,265 issued May 24, 2011. Galipeau J. and Rafei M.
3. INTERLEUKIN-2/SOLUBLE TGA-BETA TYPE II RECEPTOR B CONJUGATES AND METHODS AND USES THEREOF. U.S. Patent # 8,283,449 B2 issued October 9, 2012. Inventors: Claudia Penafuerte and Galipeau J.
4. GMCSF AND INTERLEUKIN 4 CONJUGATES, COMPOSITIONS, AND METHODS RELATED THERETO. US Patent #9,657,076 B2 issued May 23, 2017 Galipeau J. and Deng J.
5. COMPOSITIONS, USES, AND PREPARATION OF PLATELET LYSATES. U.S. Patent # 9,688,959 issued on 06/27/17. Inventors: Ian Copland and Jacques Galipeau.
Patents Provisional:
1. GMCSF AND TRUNCATED CCL2 CONUGATES AND METHODS AND USES THEREOF. Filed in the U.S. Patent and Trademark Office in June 2008. Inventors: Moutih Rafei and Galipeau J.
2. GMCSF AND INTERLEUKIN 21 CONJUGATES AND METHODS AND USES THERETO. US Provisional - assigned patent application number US 61/174,069 April 2009 Galipeau J. et al
3. CONJUGATES OF GM-CSF AND IL-7, COMPOSITIONS AND METHODS RELATED THERETO. Non-Provisional patent # 14/355,673 filed on 05/01/2014. Inventors: Jeremy Hsieh and Jacques Galipeau.
4. CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS RELATED THERETO. Provisional filed with the United States Patent Office on May 22, 2013 and assigned serial # 61/826,252. Inventors: Pingxin Li and Jacques Galipeau.
5. COMPOSITIONS OF GMCSF AND INTERLEUKIN FUSIONS FOR IMMUNE MODULATION AND USES RELATED THERETO. Provisional filed with the United States Patent Office on April 23, 2014 and assigned serial # 61/982912. Inventors: Andrea Pennati and Jacques Galipeau.
6. CHIMERIC VIRUS-LIKE PARTICLES INCORPORATING FUSION GPI ANCHORD GM-CSF AND IL-4 CONJUGATES. Provisional filed with the United States Patent Office on April 29, 2015 and assigned serial # 62/154,256: Inventors: Wang Baozhong, Richard Compans, Jacques Galipeau and Jiusheng Deng.
7. COMPOSITIONS AND CONJUGATES COMPRISING AN INTERLEUKIN AND POLYPEPTIDES THAT SPECIFICALLY BIND TGF-BETA. PCT/US2016/036358 entered the national phase in the United States on December 8, 2017 and was assigned Serial No. 15/735,158 Inventors: Jacques Galipeau and Spencer Ng.
Teaching Activities:
Emory Graduate Courses - Lecturer
• Innovations in Translational Medicine 351 HCT/Ps, IND requirements, Clinician and Sponsor Responsibilities. MSCR 592 “Clinical Research Colloquium”- Course Coordinator Igho Ofotokun, MD, MSc. March 26th 2014, March 17th 2015.
• Stem Cells, iPSCs. IBS 556 Cancer Biology – Course coordinator Lawrence Boise, PhD. March 28th 2014
• Cancer Immunotherapy. IBS524 Cancer Biology II 2015 Spring – Course coordinator Sumin Kang, PhD. February 24th, 2015.
• Ethical Considerations for Clinical Trials. Laney Graduate School Program for Scholarly Integrity – Course coordinator Brian Evavold, PhD. September 22nd 2014, August 31st 2015.
McGill Graduate Courses - Lecturer
• Gene transfer to hematopoietic stem cells. Physiology of Blood graduate course: 516 B - Dept of Physiology, McGill University - Course Coordinator Premsyl Ponka, Ph.D. 1998, 1999, 2000, 2001, 2002, 2003, 2004, 04/2005, 2006, 2007, 2008, 2009
• Gene therapy. Graduate course – Issues in Biomedical Research: 519-605B - Dept of Surgery, McGill University - Course Coordinator Pnina Brodt, Ph.D. 1999, 2000, 2001, 2002
• Cancer Gene Therapy. Graduate course – Molecular and cellular Biology Topics: 516-616A – Department of Experimental Medicine, Course Coordinator Stéphane Richard, PhD. 1998, 1999, 2000, 2001, 2002, 2003
• Cancer Gene Therapy. Graduate course – Experimental & Clinical Oncology Course 516-635D, Course Coordinator Wilson Miller. 2002, 2003, 2005, 2006, 2007, 2008
• Gene Therapy. Graduate course – Human Genetics 670. Department of Medical Genetics Fall 2004.
• Cancer Gene Therapy. Graduate course – Cellular and Applied Immunology Course PHGY 513B, Course Coordinator Julie Desbarats. 2006, 2007, 2008
• Regenerative Medicine and Cell Therapy. Graduate course – Cellular and Applied Immunology Course PHGY 513B, Course Coordinator Julie Desbarats. 2009
McGill Undergraduate Courses - Lecturer
• Cell and Gene Therapy. Undergraduate course - Biology 177-468B « Topics on the Human Genome » - Department of Biology, Course Coordinator Dr. Rima Rozen. 2002
• Cancer and Oncogenes 1 & 2. Undergraduate Medical School course (McGill University) small group lecture, Course Coordinator Dr. Pierre Laneuville. 2001, 2002
• Cancer and Oncogenes. Undergraduate Medical School course (McGill University) small group lecture, Course Coordinator Dr. G. Shenouda 2003, 2004, 2005
• Gene Therapy. Undergraduate Medical School course (McGill University), Unit 8: Pathobiology, Prevention and Treatment of Disease - INDS 208A. Department of Medical Genetics 2004, 2005, 2006, 2007
• A Conceptual Approach to Hematological Malignancies. Undergraduate Medical School course (McGill University), Unit 5: Hematological and musculoskeletal systems – INDS 102. Department of Medicine March 2005, March 2006
• Stem Cells and Regenerative Medicine. Undergraduate Medical School course (McGill University), Unit 8: Pathobiology, Prevention and Treatment of Disease - INDS 208A. Department of Medical Genetics 2008
Clinical Teaching
• Ward Attending, Clinical Teaching Unit (Internal Medicine): SMBD-JGH: 2 weeks in November 1998; 4 weeks in May 1999; 4 weeks in April 2000, 4 weeks in September 2000, 4 weeks in September 2001, 4 weeks in May 2003, 4 weeks in April 2004, 2 weeks in October 2004, 2 weeks in May 2005, 3 weeks June 2006, 2 weeks March 2007, 2 weeks November 2007, 2 weeks December 2008.
• “Back to basics” ambulatory care teaching program for 4th year Medical Students (McGill Faculty of Medicine) from January-March 1999, January-March 2000, January-March 2001
• “Introduction to Clinical Medicine-A” Clinical Teaching to Medical Student (McGill Faculty of Medicine) January 2000, January 2001
• Oral anticoagulation lecture. (Dept of Medicine, McGill University), Course Coordinator April Shamy, M.D. Hematology rounds 1999, 2001, 2002
• Family Medicine CME (SMBD-Jewish General Hospital) on “MGUS and its management” February 2000
• “Introduction to Clinical Medicine-B” Clinical Medicine teaching to Medical students (McGill Faculty of Medicine) from March until May 1998.
• “Anemia” small group teaching as part of the “Basis of Medicine” course series for 1st year McGill Medical Students – February 2003, February 2004
• “Coagulation” small group teaching as part of the “Basis of Medicine” course for 1st year McGill Medical Students – February 2005.
• “Gammopathies” seminar given at the McGill Faculty of Medicine 57th Annual Refresher Course for Family Physicians (November 27th 2006)
Mentored Junior Faculty (current)
□ Elizabeth Stenger, MD, Assistant Professor, Dept of Pediatrics, Emory University (September 2014 – current)
□ Recipient of a KL2 award (Mentor: J. Galipeau) 2014-2016
□ Recipient of a K23 award (Mentor: J. Galipeau) 2016-current
□ Muna Qayed, MD, Assistant Professor, Dept of Pediatrics, Emory University (September 2014 – current)
□ Recipient of a KL2 award (Mentor: J. Galipeau) 2016-current
□ Raghavan Chinnadurai, PhD, Assistant Scientist, Dept of Hematology and Medical Oncology, UW-Madison (December 2016 – current)
□ Andrea Pennati PhD, Assistant Scientist, UWCCC, UW-Madison (September 2016 – current). Previously was a PDF Emory University (June 2011 – August 2016)
□ Pradyut Paul, PhD, Assistant Scientist, UWCCC, UW-Madison (July 2017 – current).
Research Trainees supervised
Graduate Students (current):
□ Christopher Lewis, MD-PhD Program, Dept of Immunology and Microbiology, Emory University (July 2013 – current)
Postdoctoral Fellow (current):
□ Jayeeta Giri, PhD, UWCCC, UW-Madison (April 2017 – current).
Former Students:
• Abdulaziz A. Al-Khaldi, MD, Dept of Surgery, McGill University, (July 2000 – June 2001) – MSc degree obtained
• Al Sabti, Hilal MD, Dept of Surgery, McGill University, (July 2001 – June 2002) – MSc degree obtained
• Kapil Sharma, MD, Dept of Surgery, McGill University, (July 2002 – June 2003) – MSc degree obtained
• Aziz Chentoufi, PhD (July 2002 – July 2003) Recipient of a Wyeth-Ayerst Canada and CIHR Rx&D Research Program Post-Doctoral Fellowship (2002-2003)
• Diana Jaalouk, Dept of Experimental Medicine, McGill University, (January 1998 – October 2003) – PhD degree obtained
□ Recipient of a Cancer Research Society Inc. Scholarship (October 2000 – October 2001),
□ Recipient of the McGill Faculty of Medicine Internal Scholarship (October 1999 – October 2000)
□ Winner of the 1999 Berlex Canada Research Award in Hematology awarded for “excellence in the field of hemato-oncologic research in Canada” for abstract presented at the 41st meeting of the American society of haematology
□ Winner of The H. L. Goldsmith Research Day Awards for best presentation at the Department of Experimental Medicine (McGill University) Annual Meeting, March 2001.
□ Winner of The First Prize for best Immunology & Virology Poster at the 2nd Annual Department of Experimental Medicine (McGill University) Meeting, March 2002.
• Finalist for best poster presentation at “The Next Generation Biocontact/CIHR” meeting held in Quebec City October 2002.
• Sébastien Landry, Dept of Experimental Medicine, McGill University, (September 2001 – October 2003) – MSc degree obtained
• Recipient of a Scholarship from the Stem Cell Network (NCE), September 2001-2003
• Patricia Pelletier, M.D., Dept of Medicine, McGill University, (October 2003 – October 2005)
• John Stagg, PhD Program, Dept of Experimental Medicine, McGill University, (November 1999 – 2005, graduate with Dean’s Honors List Mention)
□ Winner of the First Prize for best poster presentation at the 1st Annual Department of Experimental Medicine (McGill University) Student’ Meeting, March 2001.
□ Winner of the Second Prize for best poster presentation at the 2nd Annual Department of Experimental Medicine (McGill University) Student’ Meeting, March 2002.
□ Winner of the First Prize for best poster presentation at “The Next Generation Biocontact/CIHR” meeting held in Quebec City October 2002.
□ Winner of the First Prize for best poster presentation at “BioNorth 2002” conference held in Ottawa November 2002.
□ Recipient of a FRSQ studentship 2003-2006.
□ Winner of the Second Prize for best poster presentation at “The Next Generation Biocontact/CIHR” meeting held in Quebec City October 2004.
• Sabrina Perri, PhD Program, Dept of Experimental Medicine, McGill University, (September 2000 – February 2007) – PhD degree obtained
□ Recipient of the Gertrude and Charles Clark Cancer Research Fellowship, April 2001, renewed 2002
□ Recipient of the McGill Faculty of Graduate Studies and Research Fellowship 2001-2002
□ Recipient of a CIHR Scholarship from the Canadian Prostate Cancer Research Initiative 2002-2005
□ Recipient of a US Army Breast Cancer Research Doctoral Fellowship (2002-2005)
□ Finalist at the 2003 Québec BioContact “prix à la relève” competition for best poster.
□ Winner of the First Prize for best poster presentation at “BioNorth 2003” conference held in Ottawa November 2003.
• Nicoletta Eliopoulos, Ph.D. (March 1999 – December 2006),
□ US Army Breast Cancer Research Post-Doctoral Fellowship (2002-2005)
□ Leukemia Research Council of Canada Scholar (Post Doctoral Fellowship) (July 2000- July 2002)
□ Winner 3rd prize for best presentation/poster at BioContact/CIHR meeting in Quebec, October 10-12, 2001
□ Winner of the First Prize for best poster presentation at “The Next Generation Biocontact/CIHR” meeting held in Quebec City October 2003
□ Terrence Kucic, Dept of Medical Genetics, McGill University (September 2005 – December 2007) – MSc degree obtained
□ Recipient of a CIHR Scholarship 2006-2009
□ Ian Copland, Ph.D. (Postdoctoral Fellow December 2004 – June 2008)
□ CIHR Postdoctoral Fellowship 2005-2008
□ Philippe Campeau, MD (Medical Genetics Fellow, September 2007 – October 2008)
□ Moutih Rafei, PhD, Dept of Experimental Medicine, McGill University (January 2004 – April 2009)
□ Montreal Centre for Experimental Therapeutics Research Award in 2007
□ Recipient of a FRSQ MSc studentship 2007-2008.
□ Recipient of a FRSQ PhD studentship 2008-2011
□ Merck-Frosst 2nd Prize for Best Oral Scientific Presentation in 2007
□ American Society of Hematology Travel Award in 2007
□ CIHR/FRSQ/IRIC/MCETC 2nd Prize for Best Poster Presentation in 2007
□ International Society of Cell Therapy (ISCT) 2008 Young Investigator Award
□ LDI Research Day 1st Prize for Best Oral Scientific Presentation in 2008
□ 4th Canadian Gene Therapy & Vaccines Symposium Award in 2008
□ Francois Mercier, MD (Heamatology Fellow, September 2007 – July 2010)
□ Manaf Benchatouf, PhD (September 2007 – September 2010)
□ Recipient of a FRSQ Postdoctoral Fellowship 2008-2011.
□ Daniel Legault-Coutu, PhD Program, Dept of Experimental Medicine, McGill University (September 2004 – March 2011)
□ Recipient of a Scholarship from the Stem Cell Network (NCE), September 2004-2005
□ Recipient of a FRSQ MSc Studentship 2005-2007
□ Recipient of a FRSQ PhD Studentship 2008-2011
□ Claudia Penafuerte, PhD Program, Dept of Experimental Medicine, McGill University (September 2004 – February 2011)
□ Recipient of a PhD studentship from the Montreal Centre for Experimental Therapeutics in Cancer (CIHR Training grant) October 2004-2005
□ Recipient of a US Army Breast Cancer Research Doctoral Fellowship (2006-2009)
□ Moira Francois, PhD Program, Dept of Experimental Medicine, McGill University (September 2006 – February 2011)
□ Recipient of a Cole Foundation Scholarship 2007-2008
□ Recipient of a FRSQ Studentship 2007-2009
□ Recipient of a CIHR Studentship 2008-2011
□ International Society of Cell Therapy (ISCT) 2008 Young Investigator Award
□ Patrick Williams, MD-PhD Program, Dept of Experimental Medicine, McGill University (January 2007 – January 2011)
□ Recipient of a CIHR MD/PhD studentship 2007-2010
□ Pingxin Li PhD, Dept of Hematology and Medical Oncology, Emory University (January 2011 – December 2012)
□ Jeremy Hsieh, MD-PhD Program, Dept of Experimental Medicine, McGill University (January 2009 – August 2013)
□ Recipient of a CIHR MD/PhD studentship 2009-2012
□ Seema Patel, PhD, Dept of Hematology and Medical Oncology, Emory University (January 2012 – March 2014)
□ Spencer Ng, MD-PhD Program, Dept of Immunology and Microbiology, Emory University (May 2011- July 2016)
□ Jiusheng Deng PhD, Instructor, Dept of Hematology and Medical Oncology, Emory University (August 2011 – August 2016)
□ Recipient of a Winship Robbins Scholarship
International Exchange Students:
□ Yuanqing (Natalie) Wu (2013-2015)
□ Emily Li (2015-2016)
Summer Students:
• Robert Varadi, Medical student, Faculty of Medicine, McGill University, (Summer 1999 – Winter 1999/2000)
□ Recipient of a McGill Summer Bursary Scholarship (1999) and Winter Scholarship (1999-2000)
• Jessy Shustick, Medical student, Faculty of Medicine, McGill University, (Summer 2000)
□ Recipient of a McGill Summer Bursary Scholarship (2000)
• Francois Mercier, Medical student, Faculty of Medicine, McGill University, (Summer 2000, Winter 2000, Summer 2001, Winter 2001)
□ Recipient of a McGill Summer Bursary Scholarship (2000) and Winter Scholarship (2000-2001)
□ Winner of the Merck Sharpe Dohme Award in Therapeutics for best summer project (2000)
□ Recipient of a Leukemia Research Foundation Summer Bursary Scholarship (2001)
□ Winner of the William V. Victor Memorial Award for best winter science project (2001)
• Simon Authier, Veterinary Medicine student, Faculty of Veterinary Medicine, Université de Montréal, (Summer 2001)
□ Recipient of a NSERC Summer Bursary Scholarship (2001)
• Marianne Girard, Veterinary Medicine student, Faculty of Veterinary Medicine, Université de Montréal, (Summer 2001)
□ Recipient of a NSERC Summer Bursary Scholarship (2001)
• Nathaniel Bouganim, Medical student, Faculty of Medicine, McGill University, (Summer 2002)
□ Recipient of a McGill Summer Bursary Scholarship (2002)
□ Recipient of a McGill Winter Bursary Scholarship (2002)
• Alexandre Cengarle-Samak, Medical student, Faculty of Medicine, McGill University, (Summer 2003)
□ Recipient of the Rona & Irving Levitt Family Foundation Scholarship Program in Oncology (2003)
• Gerardo David Camoriano, Medical student, Faculty of Medicine, McGill University, (Summer 2003)
□ Recipient of a CIHR/RxD Health Research Foundation Summer Research Studentship in Medicine (2003)
• Chenjie Xia, Medical student, Faculty of Medicine, McGill University, (Summer 2004)
• Recipient of a CIHR/RxD Health Research Foundation Summer Research Studentship in Medicine (2004)
• Recipient of a McGill Faculty of Medicine Winter Research Studentship in Medicine (2004-5)
• Patrick Willliams, Medical student, Faculty of Medicine, McGill University, (Summer 2006)
• Recipient of a McGill Faculty of Medicine Summer Research Studentship in Medicine (2006)
• Jiamin Zheng, Medical student, Faculty of Medicine, McGill University, (Summer 2008)
• Recipient of a McGill Faculty of Medicine Summer Research Studentship in Medicine (2008)
• Jeremy Hsieh, Medical student, Faculty of Medicine, McGill University, (Summer 2008)
• Recipient of the John H. Altshuler Research Award in Hematology McGill Faculty of Medicine Summer Research Studentship in Medicine (2008)
Honors Students:
• Mylene Dandavino, Dept of Immunology, McGill University, (Winter semester 1998)
• Pierre-Alain Hueber, Dept of Biology, McGill University, (Winter semester 2001)
• Jeremy Hsieh, Dept of Immunology, McGill University (Winter semester 2006)
• Amanda Abate, Dept of Immunology, McGill University (Winter 2007, Summer 2008)
• Jakob Habib, Summer Undergraduate Research Program at Emory (SURE), Emory University (Summer 2012)
• Jenna Sands, Summer Undergraduate Research Program at Emory (SURE), Emory University (Summer 2016)
Visiting Professor and Mentored Faculty
□ Dr. Daniel Martineau (Associate Professor at Montreal University School of Veterinary Medicine) May 2000 to September 2001.
□ Ian Copland PhD, Assistant Professor, Dept of Hematology and Medical Oncology, Emory University (October 2010 – July 2015)
□ Recipient of a Winship Robbins Scholarship
Research Assistants & Associates
• André Paquin, MSc, November 1997 – February 2000
• Milena Crosanto, MSc, December 1999 – April 2004
• Sandra Pommey, September 2004 – October 2005
• Moira François, November 2003 – September 2006
• Laurence Lejeune, BSc, August 2000 – January 2008
• Marie-Noelle Boivin, MSc, June 2006 – October 2009
• Elena Birman, October 2007 – September 2010
• Kathy Forner, February 2007 – December 2010
• Norma Bautista-Lopez PhD, April 2008 – December 2010
• Jing Xhao, June 2007 – March 2011
• Jessica Cuerquis, BSc, September 2003 – March 2011
• Raphaelle Romieu, PhD, October 2005 – March 2011
• Jordan Murphy, June 2012 – April 2014
• Shala Yuan, April 2004 – current
Invited Presentations:
1. Thérapie génétique des maladies hématologiques. Conférencier à la réunion scientifique annuelle de l’Association des Médecines biochimistes du Québec (Novembre 1997), Hotel Vogue, Montréal.
2. VSV-G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Invited lecturer at the Canadian Association for Medical Oncologists Meeting held in Toronto, April 1999.
3. Vesicular Stomatitis G pseudotyped retrovectors for tumor targeted gene delivery in vivo. Invited speaker at the “premier colloque de l’association de thérapie génique du Québec” held at Sherbrooke University, April 16th, 1999.
4. Invited Expert on Cancer Immunization for the Canadian Advisory Board on Immunization in Ottawa, Canada – June 15, 1999.
5. Gene therapy of brain cancer with pseudotyped retrovectors. Invited Speaker at St. Jude Children’s Research Hospital (Department of Neuro-Oncology) – August 19th, 1999.
6. Cancer Gene Therapy – Molecular Medicine for the 3rd Millennium. Department of Medicine Grand Rounds – SMBD/JGH – November 29th, 1999
7. Gene Therapy. Invited speaker at the 4th Annual Meeting of the Canadian Diabetes Association (Halifax October 2000)
8. Thérapie génétique du cancer. Invited speaker at the Université de Montréal Faculty of Veterinary Medicine in St-Hyacinthe, Canada – November 2, 2000.
9. Cell and Gene Therapy of Cancer. Hematology-Oncology rounds – Montreal General Hospital – February 28th, 2001
10. Bone marrow stromal cells as a vehicle for transgenic cell therapy of disease. Invited speaker at the Centre de Recherches en Reproduction Animale (CRRA) Université de Montréal Faculty of Veterinary Medicine in St-Hyacinthe, Canada – November 1, 2001.
11. Cell and Gene therapy of Disease. Department of Medicine Grand Rounds – SMBD/JGH – January 14th 2002
12. Genetically Engineered Stromal Cells for Therapy of Disease. Department of Anatomy and Cell Biology – McGill University – January 16th 2002
13. Genetically Engineered Stromal Cells for Therapy of Disease. Department of Radiation Oncology – Montreal General Hospital (McGill) – January 21st 2002
14. Retrovirally Engineered Autologous Marrow Stromal Cells for Cell Therapy of Disease. Department of Human Genetics – Montreal Children’ Hospital (McGill) – February 8th 2002
15. Retrovirally Engineered Autologous Marrow Stromal Cells for Cell Therapy of Disease. Seminar Series of the Department of Obstetrics and Gynecology – Royal Victoria Hospital (McGill) – February 14th 2002
16. Genetically-engineered marrow stromal cells for therapy of acquired disease – A marriage of stem cell plasticity and gene therapy. Invited speaker at the Ottawa Hospital Research Institute/Comprehensive Cancer Center combined Seminar series, February 22nd 2002.
17. Gene modified bone marrow stroma. Invited speaker at the Southern Ontario Gene Therapy Meeting (Cambridge, Ontario April 2002)
18. Genetically-engineered marrow stromal cells for therapy of disease – A marriage of stem cell plasticity and gene therapy Children's Hospital Research Institute Seminar Series - Montreal Children’ Hospital (McGill) – May 6th 2002
19. Genetically-engineered marrow stromal cells for therapy of acquired disease – A marriage of stem cell plasticity and gene therapy. Invited speaker at the University of Louisville Research Center (Louisville, Kentucky August 26th 2002.)
20. Exploiting stromal cell plasticity for development of genetically-engineered biosynthetic organoids. Invited research presentation at the 2002 Annual General Meeting of the Canadian Stem Cell Network (Mississauga, Ontario September 27th 2002)
21. Suicide Gene Therapy for the Treatment of Cancer. Invited speaker at the 10th Oncology Congress Venezuelan Oncology Society (Caracas, Venezuela 10-12 Oct-2002)
22. Cell and Gene Therapy – A Novel Approach to the Treatment of Cancer Invited speaker at the 39th Annual André Aisenstadt Memorial Clinical Day – Jewish General Hospital – October 23rd 2002.
23. Genetically-engineered marrow stromal cells for cellular immunotherapy of cancer McGill Immunology Seminar 2002 – Department of Immunology – November 27th 2002
24. Gene Therapy in hematology. Invited speaker at the 28th Congress of the Association de Médecins Hématologistes-Oncologistes du Québec (AMHOQ). (Mont Ste-Anne, Québec March 29th 2003)
25. Gaucher’s Disease: Contemporary Management and Societal Impact. Jewish General Hospital Department of Medicine Grand Rounds – March 31st 2003.
26. Gaucher Disease: Evidence-based management. Medical Grand Rounds Royal Victoria Hospital – October 22nd 2003.
27. «Cellules souches et thérapie génique combinés pour la synthèse de biopharmaceutiques cellulaires transgéniques». Invited speaker at the University of Montreal Department of Biochemistry seminar series (Montreal, October 28th 2003)
28. A Model for Pilot Regenerative Medicine Clinical Trials in the Canadian Research Hospital Environment. Invited speaker at the 10th Annual International Life Sciences Conference and Exhibition (Ottawa, November 17th 2003)
29. «Thérapie génique et cellulaire – une nouvelle stratégie biopharmaceutique». Invited speaker at the 28th annual meeting of the Association des biologistes du Québec (Montreal, December 4th 2003)
30. Transgenic Stem Cell Therapy – A biopharmaceutical platform for plasma protein delivery. Invited speaker at the 2004 Southern Ontario Gene Therapy Meeting (Cambridge, Ont. May 3rd 2004).
31. Controversies in Hemophilia Gene Therapy. Invited speaker at The Canadian Hemophilia Summit (Toronto, Ont. September 30th 2004)
32. Allogeneic Murine Marrow Stromal Cells are Immune Rejected by Immunocompetent MHC Class I and II Mismatched Recipient Mice. Invited speaker at the 4th Annual Conference on Mesenchymal and Nonhematopoietic Stem Cells Meeting: Focus on Adult Stem Cells (New Orleans, LA October 15th 2004)
33. Genetically Engineered Marrow Stromal Cells – A biopharmaceutical platform for erythropoietin delivery in vivo. Invited speaker at the London Regional Cancer Center Seminar Series, University of Western Ontario (London, Ont. January 26th 2005)
34. Gene Therapy. Invited Lecturer for the BIOL 461/4, Advanced Genetics, Concordia University Winter 2005. February 9th 2005. Course coordinator: Dr. Cathy Doiron.
35. Erythropoietin Gene Enhanced Marrow Stromal Cells – A Biopharmaceutical Platform for Therapy of Renal Anemia. Invited speaker at the 2005 Southern Ontario Gene Therapy Meeting (Cambridge, Ont. April 17th 2005).
36. GM-CSF/ IL-2 Fusion Transgene (GIFT) and IL-2 secreting marrow stromal cells: novel means for cancer immunotherapy. Invited speaker at the Centre hospitalier de l’université du Québec (CHUQ) – Hotel-Dieu de Québec (Québec, Québec April 21st 2005).
37. « La rédaction de demandes de subventions ». Invited speaker at the 4ième journée de recherche du Réseau québécois de recherche sur le vieillissement – Centre Mont-Royal (Montreal, April 29th 2005)
38. "Genetically-engineered Marrow Stromal Cells for cancer immunotherapy" Invited speaker at the Centre Hospitalier Université de Montréal, Notre-Dame Campus Cancer Center Seminar Series (Montreal May 25th 2005).
39. Grants, Grantsmanship and the Heisenberg Principle of Uncertainty. McGill University Research Grants Office Grantsmanship Meeting – June 9th 2005.
40. Cell and Gene Therapy: A Clinical Perspective. McGill Medical Genetics Training Program - Friday Lecture and Seminar Series. Friday June 17th 2005.
41. IFN(-Stimulated Marrow Stromal Cells (MSCs): A new type of Non-Hematopoietic Antigen-Presenting Cell. Invited speaker at the 8th Quebec Gene Therapy Association Colloquium (Montreal, October 28th, 2005)
42. Cell and Gene Therapy of Cancer: A Clinical Perspective. MUHC-R1 Genetics Axis and McGill Department of Human Genetics Seminar Series. Montreal Children’s Hospital, Friday November 11th 2005.
43. The immune plasticity of Marrow Stromal Cells. Invited speaker at the McMaster University Center for Gene Therapeutics (Hamilton, January 11th 2006)
44. Tissue regeneration and angiogenesis: Keys to the future of repair?. Invited speaker at the CIHR Institute for Cardiac and Respiratory Health Symposium: From Idea to Action in Circulatory and Respiratory Health Research (Vancouver, March 2nd, 2006)
45. Stem Cell Research in Canada. Invited speaker at the Yale/UConn Second Stem Cell Retreat (North Haven, CT March 8th 2006)
46. Blood and Marrow Stem Cells for Heart Repair. Invited speaker at the 26th Annual General Meeting of the Canadian Apheresis Group (Val-David, April 9, 2006)
47. Marrow Stromal Cells as Conditional Antigen Presenting Cells. Invited plenary speaker at the International Society for Cellular Therapy’s 12th Annual Meeting, Berlin, May 5th 2006.
48. Gene Therapy for Leigh’s Syndrome French Canadian type: Theoretical considerations. Invited speaker at the 1st International Colloquium on LSFC, Montreal, May 10th 2006.
49. Cellules mésenchymateuses en médecine régénérative. Invited speaker at the 74th annual meeting of the Association francophone pour le savoir (ACFAS) colloquia on regenerative and nanomedicine. Montreal, May 16th 2006.
50. The Generation of a GMCSF-IL15 transgene (GIFT15) with novel immunosuppressive properties. Invited speaker at the Meakins-Christie Laboratories beer seminar series. Monday October 2nd 2006.
51. The Generation of a GMCSF-IL15 transgene (GIFT15) with novel immunosuppressive properties: Potential use in tolerance induction to allogeneic and xenogeneic tissue transplantation. Joint seminar series: Departments of chemistry and Biomed université du Québec à Montréal. Wednesday November 1st 2006
52. Genetically engineered Mesenchymal Stromal Cells and their use as a cellular pharmaceutical. Invited plenary speaker at the 2006 Annual General Meeting of the Canadian Stem Cell Network. Ottawa November 15th 2006.
53. Immune plasticity of mesenchymal stromal cells and their use as a cell-based biopharmaceutical. Invited plenary speaker at the Inauguration of the Sprott Center for Regenerative Medicine (Ottawa Health Research Institute). Thursday November 16th 2006.
54. The Immune plasticity of Mesenchymal Stromal Cells and Their Experimental Use in Cell Based Therapeutics. Invited speaker at the Sunnybrook Health Sciences Center Molecular and Cellular Biology Research Seminar Series. Toronto, Wednesday November 22nd 2006.
55. Immune modulation by Mesenchymal Stromal Cells and Potential Clinical Use. Invited speaker at the Groupe de recherche sur le sang de cordon Ste-Justine Hospital (University of Montreal) December 4th 2006.
56. Erythropoietin Gene-Engineered Mesenchymal Stromal Cells for Treatment of Anemia. Invited speaker at the University of Montreal Department of Pharmacology Conference series. Montreal, Thursday March 15th 2007.
57. Genetically engineered Mesenchymal Stromal Cells and their use as a cellular pharmaceutical. Invited speaker at the CGCF/CGDN 16th Annual Scientific Meeting April 19 – 22, 2007 Saint-Sauveur, PQ.
58. Towards computational design of 3D scaffolds for cell-based gene therapy. Invited speaker at the NRC CompMed (Computer Simulation in Medicine) Conference May 16-18 2007, Industrial Materials Institute, Boucherville, PQ.
59. Traitement combiné pour la maladie de Gaucher: inhibiteur de substrat et enzyme de remplacement. Invited speaker at the Association des conseillères et conseillers en génétique du Québec Montreal, May 25th 2007.
60. Genetically Engineered Mesenchymal Stromal Cells and their use as a Cellular Pharmaceutical. Invited guest speaker at the Department of Life Sciences, Central China Normal University, Wuhan, China. September 11th 2007
61. Genetically-Engineered Mesenchymal Stromal Cells for Treatment of Myocardial Infarction. Invited speaker at the Cell Transplant Society/International Pancreas and Islet Transplant Association/International Xenotransplantation Association 2007 Joint Conference September 15-20, 2007. Minneapolis, Minnesota.
62. Sang de cordon et medicine réparatrice. Invited speaker at the Symposium sur le sang de cordon. CHU Ste-Justine (Montreal, Quebec), Wednesday November 7th 2007.
63. The challenges of taking therapies into a GMP environment. Invited speaker at International Consortium of Stem Cell Networks workshop on GMP issues in stem cells. International Centre for Life, Newcastle, UK. Thursday 15 November 2007
64. A novel type of suppressor cell for therapy of autoimmune disease. Invited speaker at the CHU Hopital Maisonneuve-Rosemont (University of Montreal) Hematology Research Rounds November 23rd 2007.
65. Mesenchymal Stromal Cells for suppression of acquired autoantibodies. Invited speaker at the CHU Ste-Justine (Montreal, Quebec) Research Institute seminar series, Friday January 18th 2008.
66. Mesenchymal Stromal Cells produce cleaved CCL2: a potent inhibitor of Th2 immune response. Invited speaker at the University of Montreal Department of Immunology and Bacteriology Seminar series, Thursday April 3rd 2008.
67. Mesenchymal Stromal Cells for therapy of hematological disorders. Invited speaker at the 11th Biennal Canadian Bone Marrow Transplant Group (CBMTG) Conference. Montreal, April 9 2008.
68. Stem Cells. Invited speaker at the Institute of Circulatory and Respiratory Health Young Investigators (YI) Forum in Montreal, QC. May 10th 2008.
69. Mesenchymal Stromal Cells are immune modulatory cells which inhibit Th2 immune response via their production of an antagonistic cleaved form of CCL2. CIHR Seminar Series, Multi Organ Transplant Program, University Health Network, Toronto, May 13th 2008.
70. A Clinician’s Perspective on Research Risk. Invited speaker at the McGill Annual Workshop for Research Ethics Board Members and Researchers. Tuesday May 13th 2008.
71. A synthetic fusokine borne of the marriage of GMCSF and IL15 allows for production of B regulatory cells with potent immune suppressive effects in vivo: validation in a mouse xenoimplant model and multiple sclerosis. Invited speaker at the CIHR Strategic Training Program in Regenerative Medicine Visiting Lecture Series. Toronto, May 14th 2008.
72. Mesenchymal Stromal Cells Gene-Engineered to Produce Erythropoietin for Treatment of Ischemic Cardiovascular Disease. Invited speaker at the American Society of Gene Therapy Symposium on Embryonic/Somatic Stem Cell and Tissue Engineering: Stem/Progenitor Cells as Delivery Vectors for Disease Targets. Boston, May 19th 2008.
73. A synthetic fusokine borne of the marriage of GMCSF and IL15 allows for production of B regulatory cells with potent immune suppressive effects in vivo: validation in a mouse xenoimplant model and multiple sclerosis. Guest speaker at the Emory Winship Cancer Center, Atlanta, GA, August 25th 2008.
74. Mesenchymal Stromal Cells as Conditional Antigen Presenting Cells for Cancer Immunotherapy. Guest speaker at the UT-M.D. Anderson Cancer Center Apoptosis Working Group Seminar, Houston, Texas, September 3rd 2008.
75. Marrow Mesenchymal Stromal Cells Express Periostin: The Lead Member of a New Family of γ-Carboxylated Matrix Proteins. Invited Symposium Speaker at the 30th Annual Conference of the American Society for Bone and Mineral Research. Montreal, Canada, September 15th 2008.
76. A synthetic fusokine borne of the marriage of GMCSF and IL15 allows for production of B regulatory cells with potent immune suppressive effects in vivo: validation in a mouse xenoimplant model and multiple sclerosis. Invited speaker at the Centre Hospitalier de l’université de Montréal Transplantation Seminar Series. CHUM Notre-Dame, Montreal, October 17th 2008.
77. Stem Cells: Dream or Illusion? Symposium given to a general public audience as part of the McGill Mini-Med series 2008. McGill University, Montreal. October 22nd 2008.
78. Stem Cells and their use as a Cellular Pharmaceutical. Invited speaker at the Canadian Institute for Health Research Regenerative Medicine and Nanomedicine Initiative Day. CIHR, Ottawa, October 23rd 2008.
79. Mesenchymal Stromal Cells: Potential Mechanisms of Action in Autoimmune Disease. Invited speaker at the Consortium of Multiple Sclerosis Centers’ conference on Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis. Paris, France, March 11th 2009.
80. Incorporating Gene and Stem Cell Technologies to your Practice. Invited Symposium Speaker as part of a comprehensive review for Obstetricians and Gynecologists and Family Physicians as part of the McGill – sponsored “Expanding the Horizon of Obstetrics & Gynecology” series, Friday April 3rd 2009, Montreal.
81. Mesenchymal Stromal Cell Suppression of Autoimmune Response Arises from Production of an Antagonistic Variant of CCL2. Invited symposium speaker at the American Association of Anatomist’s sponsored Stem Cell Mini-Meeting as part of the Experimental Biology 2009 Annual Meeting in New Orleans, LA April 21st 2009.
82. A novel type of Breg for cell therapy of immune disease. Invited Plenary Speaker at the 2009 Langdon Hall Gene Therapy Meeting, Cambridge, Ontario May 28th 2009.
83. Mesenchymal Stromal Cells for Therapy of Autoimmune Disease. Invited Speaker at the 2009 Canadian Society of Transfusion Medicine Annual Meeting. Ottawa, Ontario June 5th 2009.
84. A regenerative medicine approach for the treatment of myocardial infarction using myeloid cells. Speaker at the Emory Division of Cardiology Cardiovascular Biology Seminar. Atlanta, GA. Monday November 9th 2009.
85. Personalized cellular medicine for treatment of autoimmune ailments. Speaker at the Egleston 2009 Pediatrics Research Grand Rounds. Wednesday November 11th 2009.
86. Immune Plasticity of human MSC in response to inflammatory cytokines as a predictive assay for suppressor function and potency. Invited speaker at the 5th international conference on Mesenchymal and non-Hematopoietic Stem Cells held in Austin, Texas, November 14th, 2009.
87. Mesenchymal Stem Cells in Suppression of Inflammation, Tissue Repair and Immune Modulation. Invited Speaker at the American Society of Transplantation/Cell Transplant Society Symposium held during the Annual Scientific Exchange in Orlando, Florida December 6, 2009.
88. Mesenchymal Stromal Cells and Immunomodulation in Hemophilia. Invited Speaker at the Tenth Workshop on novel technologies and gene transfer for hemophilia held in Chapel Hill, North Carolina February 6th 2010
89. Personalized cellular medicine for treatment of autoimmune ailments. Speaker at the Winship Cancer Institute at Emory University Grand Rounds. March 17th 2010.
90. Mesenchymal Stromal Cells and Immunomodulation in Autoimmune Disease. From discovery to reverse engineering of novel therapeutic fusokines. Speaker at the EUH Department of Medicine Grand Rounds. Atlanta, GA. March 23rd 2010.
91. Fusokines for treatment of autoimmune ailments. Invited Speaker at the 4th World Immune Regulation Meeting held in Davos. Switzerland. April 1st 2010.
92. B-regulatory cells: A novel biopharmaceutical for treatment of catastrophic autoimmune ailments. Invited speaker at the 23rd Annual Meeting of the Canadian Society for Immunology held in Niagara Falls, Ontario. April 24th 2010.
93. Personalized cellular medicine for treatment of autoimmune ailments. Speaker at the Emory Immunology and Molecular Pathogenesis Seminar Series. Atlanta, GA. April 27th, 2010.
94. Mesenchymal Stem Cells in Suppression of Inflammation, Tissue Repair and Immune Modulation. Speaker at the Medical College of Georgia Immunotherapy Center, Augusta, Georgia, May 19th 2010.
95. Mesenchymal Stromal Cell Suppression of Autoimmune Response. From discovery to reverse engineering of novel therapeutic fusokines. Speaker at the EUH Center for Neurodegenerative Disease seminar series. Atlanta, GA. June 10th, 2010.
96. Fusokines: Novel Biopharmaceuticals for Immunotherapy. Invited speaker at the 7th Axel Key Symposium on the Molecular Basis of Applied Biological Therapeutics sponsored by the Royal Swedish Academy of Sciences. Stockholm, Sweden. September 14th 2010.
97. Enabling Experimental Cell Therapy in Georgia: A Defined Plan for First-in-human Clinical Trials at Emory. Invited speaker at a special seminar hosted by the Georgia Institute of Technology IBB Institute, Atlanta, GA. October 5th 2010.
98. Fusokines for treatment of cancer. Seminar speaker at the UGA Cancer Center, Athens, GA. November 1st 2010.
99. B-regulatory cells: A novel personalized cell therapy for autoimmune ailments. Invited speaker at Imperial College/Hammersmith Hospital Haematology Seminar, London, UK January 11th 2011
100. MSC for discovery of immune suppressive cytokines and clinical translation. Keynote speaker at Imperial College London Stem Cell Meeting, London, UK January 11th 2011
101. Fusokines: Novel Biopharmaceuticals for Immunotherapy. Invited speaker at CIHR Strategic Training Program in Biological Therapeutics, University of Toronto, Medical Sciences Building, Toronto, ON. February 8th 2011.
102. Enabling Experimental Stem Cell Therapy in IBD. Invited speaker at the Crohn’s & Colitis Foundation of America (CCFA) Advances in the Treatment and Management 2011, Emory Conference Center Hotel, Atlanta, GA. March 26th 2011.
103. Mesenchymal Stem Cells as Immunomodulators. Invited speaker at the American Transplant Congress (ATC) at the Pennsylvania Convention Center in Philadelphia, PA, April 30 – May 4, 2011
104. MSCs bite back - MSCs as antigen presenting cells for cancer immunotherapy. Invited speaker at the 17th International Society for Cell Therapy (ISCT) Annual Meeting in Rotterdam, Netherlands May 19th 2011.
105. The Immune Plasticity of MSC: Impact on Design of Cell Therapy Studies. Invited speaker at the Stem Cells and Cell Therapies in Lung Biology and Lung Disease Conference at the University of Vermont, Burlington, VT July 25-28, 2011
106. Mesenchymal Stromal Cell Suppression of Autoimmune Response. From Discovery to Design of Cell Therapy Studies. Invited speaker at Case Western Reserve University Comprehensive Cancer Center and the National Center for Regenerative Medicine, Cleveland, Ohio January 19th 2012
107. Mesenchymal Stromal Cells for Personalized Cell Therapy. From Discovery to Design of Cell Therapy Studies. Keynote Speaker at the 1st Scientific Conference of the Morehouse School of Medicine Department of Microbiology, Biochemistry and Immunology in Atlanta, March 22nd 2012.
108. Inhibition of cellular senescence by developmentally regulated FGF receptors in MSCs. Invited Speaker at the European Hematology Association and the European School of Hematology’s international scientific workshop on the anti-inflammatory and immune modulatory properties of mesenchymal stromal cells. April 20th 2012, Mandelieu La Napoule, France.
109. Mesenchymal Stromal Cell Suppression of Autoimmune Response. From Discovery to Design of Cell Therapy Studies. Invited Speaker at the University of Minnesota Department of Laboratory Medicine and Pathology Grand Rounds. May 16th 2012, Minneapolis, MN.
110. Mesenchymal Stromal Cells for personalized cell therapy: How mechanistic cell physiology studies can inform the design of clinical trials. Presidential Plenary Speaker at the International Society of Cell Therapy 18th Annual Meeting. June 6th 2012, Seattle, WA.
111. Mesenchymal Stromal Cells for personalized cell therapy: How mechanistic cell physiology studies can inform the design of clinical trials. Invited Speaker at the Institute of Health Sciences, Shanghai Institute for Biological Sciences (Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine). August 17th 2012, Shanghai, China.
112. Mesenchymal Stromal Cells for personalized cell therapy: How mechanistic cell physiology studies in NHPs can inform the design of clinical trials. Invited Speaker at the 5th International Symposium on Primate Research. August 19th 2012, Kunming, China.
113. Mesenchymal Stromal Cells for personalized cell therapy of autoimmune disease. How mechanistic cellular biochemistry can inform the design of clinical trials. Invited Speaker at the University of Montreal, Department of Biochemistry seminar series. November 6th 2012, Montreal, Canada.
114. Fusokines: Novel Biopharmaceuticals for Immunotherapy. Invited Speaker at the University of Montreal, Department of Pharmacology seminar series. November 6th 2012, Montreal, Canada.
115. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. Invited Speaker at the FDA Cell Therapy Working Group, Cellular Therapies Branch/Cellular and Tissue Therapy Branch, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. December 18th 2012, Rockville, MD.
116. Enabling Experimental Stem Cell Therapy in IBD. Invited speaker at the CCFA Advances in the Treatment and Management. 2013 March 23rd 2013, Atlanta, GA.
117. Mesenchymal Stromal Cells for personalized cell therapy of autoimmune disease. How mechanistic analysis of immune plasticity and cellular biochemistry can inform the design of clinical trials. Invited Plenary Speaker at the CIBMTR-sponsored Workshop on Transplant and Cellular Therapy for Autoimmune Diseases. April 20th 2013, Milwaukee, WI.
118. Characterization of MSCs for Clinical Applications. Invited speaker at FDA-Center for Excellence in Regulatory Science and Innovation-University of Maryland (CERSI-UMD) Workshop on Improved Characterization of Mesenchymal Stem Cells for Clinical Trials, May 8th 2013, Baltimore, MD.
119. The detrimental aspects of cryopreservation on MSCs. Invited plenary Speaker at the 23rd Regional Congress of the International Society for Blood Transfusion, June 3rd 2013, Amsterdam, The Netherlands.
120. Mechanistic analysis of mesenchymal stromal cells as veto cells in clinical applications. Invited speaker at the 18th NAT Conference, June 25th 2013, Nantes, France.
121. Mechanistic Analysis of human Mesenchymal Stromal cells as Veto Cells in Clinical Applications. Invited speaker and session Chair at the MSC 2013 Cleveland meeting, August 21st 2013, Cleveland, OH.
122. The mesenchymal stromal cells dilemma-a failure analysis of negative phase III trial of industrial mesenchymal stromal cells in steroid-resistant graft-versus-host disease. Plenary Speaker and Session Chair for “Translational development of universal donor MSC-like cellular pharmaceuticals” at the International Society of Cell Therapy North American Regional Meeting, September 9th 2013, Philadelphia, PA.
123. Novel published guidelines from ISCT MSC Committee. Invited speaker at Technical session International Society of Cell Therapy North American Regional Meeting, September 10th 2013, Philadelphia, PA.
124. Autologous mesenchymal stromal cells engineered to secrete therapeutic proteins as part of a synthetic endocrine device: pre-clinical development and roadmap to clinical use. Invited Speaker at the 11th Protein Expression in Animal Cells (PEACe) conference, September 26th 2013, Kananaskis, Alberta.
125. MSC identification/expansion (manufacturing implications) and potency assays. Invited Speaker at “Cell-based therapies: A new era in patient care” workshop hosted by Nationwide Children’s Hospital, October 14th 2013, Columbus, OH.
126. MSC product for clinical trials: manufacturing and potency considerations. Invited Speaker at the Workshop on Stem Cell Technology and Clinical Translation hosted by the Shanghai Institute of Biological Sciences, Shanghai, China, November 7th 2013.
127. The Impact of Cryopreservation on Fitness of Cell Therapy Products in Human Clinical Trials - the MSC Paradigm. Invited Speaker at 2014 Joint Meeting of the Society for In Vitro Biology and the Society of Cryobiology, June 4th 2014, Savannah, GA.
128. Fusokines: A Novel Class of Biopharmaceuticals for Enabling Cancer Cellular Immunotherapy. Invited Speaker at the Hollings Cancer Center at Medical University of South Carolina, Charleston, SC, July 29th 2014.
129. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Implementation of Cell Therapy Studies for Crohn’s Disease. Invited Speaker at the 27ème Entretiens Jacques Cartier 2014, Colloquium 3 - Stem Cells and Cancer: Seek, Understand and Destroy! Montreal, QC, October 6th 2014.
130. Fitness of Cell Therapy Products in Human Clinical Trials - the MSC Paradigm. Invited Speaker at the Center for Cancer and Immunology Research, Children’s National Health System, Washington D.C., November 19th 2014.
131. Fusokines: A Novel Class of Biopharmaceuticals for Enabling Cancer Cellular Immunotherapy. Invited Speaker at the Karmanos Comprehensive Cancer Institute, Detroit, MI, January 22nd 2015.
132. Mesenchymal Stem Cell Therapies. Invited speaker at the Association of Medical School Pediatric Department Chairs (AMSPDC) annual meeting, Newport Beach, CA, February 28th 2015.
133. Fitness of Cell Therapy Products in Human Clinical Trials - the MSC for GvHD Paradigm. Invited speaker at the EBMT/ISCT joint session on cell therapy at the European Society for Blood and Marrow Transplantation (EBMT) 41st Annual Meeting, Istanbul, Turkey, March 23rd, 2015
134. How mechanistic studies on Mesenchymal Stromal Cells inform design of human clinical trials for autoimmune ailments – The fitness paradigm. Invited speaker at the University of California at Irvine Stem Cell Research Center and Department of Pharmaceutical Sciences Seminar, Irvine, CA May 1st 2015.
135. Fitness of MSCs in human clinical trials: From discovery to implementation of cell therapy studies for Crohn’s Disease. Invited speaker at the American Society of Gene and Cell Therapy (ASGCT) 18th Annual Meeting, New Orleans, May 16th 2015.
136. The role of Academic Health Centers in developing impactful cell therapies. Invited Speaker at the Workshop on Global Regulatory Perspectives as part of the 21st annual meeting of the International Society of Cell Therapy, Las Vegas, NV May 27th 2015.
137. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. Invited Speaker at the 28th Annual Meeting of the Canadian Society of Immunology, Winnipeg, MB June 7th 2015.
138. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. Invited Speaker at the Georgia Tech Business of Regenerative Medicine Program 8th annual course as part of the State of the Science presentation in Session 3 - “Immunotherapies.” Atlanta, GA July 21st 2015.
139. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. Invited Speaker at the Innovations in Cell-Based Regenerative Therapies Conference (MSC 2015). August 17th, 2015 Cleveland, Ohio.
140. Mesenchymal Stromal cells in Solid Organ Transplantation. Invited Speaker at that State-of-the-Science Symposium in Montreal at the CRCHUM, Sponsored by the Canadian National Transplant Research Program (CNTRP), September 16th 2015, Montreal, QC.
141. Mesenchymal Stromal Cells as a cellular pharmaceutical to modulate the immune response in solid organ transplantation. Invited Speaker at the Duke University Robertson Clinical and Cell Therapy Program (CT2) Program, September 22nd 2015, Durham, NC.
142. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. Invited Speaker at the University of Wisconsin Carbone Comprehensive Cancer Center Grand Rounds. October 7th 2015, Madison, WI.
143. Mechanistic analysis of MSCs for optimized use in clinical trials. Invited Speaker for the Karolinska Institutet Doctoral Program on Regenerative Medicine on Mesenchymal Stem Cells. October 16th 2015, Stockholm, Sweden.
144. Issues related to MSC cell production. Invited Speaker at the International Conference on Cell-Based Therapy for Multiple Sclerosis sponsored by the National Multiple Sclerosis Society and the European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS]. November 20th 2015, Lisbon, Portugal.
145. The Mesenchymal Stromal Cell paradigm and how failed industrial clinical trials inform rational development of cellular pharmaceuticals. Invited Speaker at the World Stem Cell Summit 2015 (WSCS15). December 12th 2015, Atlanta, GA.
146. The MSC conundrum of unmet translational expectations-analysis and potential fixes. Keynote Speaker at the Harvard Stem Cell Institute sponsored MSC Colloquim – Roadmap to Translation. March 29th 2016, Boston, MA.
147. Fusion cytokines: A Novel Class of Biopharmaceuticals for Enabling Cancer Cellular Immunotherapy. Invited Speaker at the Dartmouth-Hitchcock Norris Cotton Cancer Center Grand Rounds. April 12th, 2016. Lebanon, NH.
148. MSC product for clinical trials: manufacturing and potency considerations. Invited Speaker at the 5th Stem Cell Product Development & Commercialization Conference as part of the Global Technology Community (GTC) 2016 Stem Cell Summit. April 27th, 2016. Boston, MA.
149. MSC product for GvHD: manufacturing and potency considerations. Invited Speaker at the 6th edition of the Annual Scientific Workshop of the Primary Immune Deficiency Treatment Consortium (PIDTC). May 21st, 2016. Los Angeles, CA.
150. The MSC Conundrum of Unmet Translational Expectations-Analysis and Potential Fixes. Chair and Invited Speaker for Technical Session on Development Pathways for MSC Based Products as part of the 24th Annual Meeting of the International Society of Cell Therapy (ISCT 2016). May 26th 2016. Singapore.
151. How mechanistic studies on Mesenchymal Stromal Cells inform design of human clinical trials for autoimmune ailments – The fitness paradigm. Chair and invited speaker at the “FDA Workshop: Scientific Evidence in Development of HCT/Ps Subject to Premarket Approval” organized by The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), September 8th, 2016 FDA White Oak Campus, Silver Spring, MD.
152. Mechanistic analysis of MSCs for optimized use in clinical trials. Invited speaker as part of the UW Stem Cell & Regenerative Medicine Center Campus Stem Cell lab meeting. September 20th 2016, Mordridge Institute for Discovery, Madison, WI.
153. MSCs: Ability, Potency and Comparability. Invited speaker at the ISCT Delivering value in cell therapy: A patient focused approach Commercialization Signature Series. September 29th 2016, St. Jude Children’s Research Hospital, Memphis, TN.
154. Mechanistic insights into MSC therapies. Invited speaker at the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) 2016 meeting. Sponsored by Die Deutschen Universitatsklinika Regensburg. October 27th, 2016. Regensburg, Germany
155. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. Invited speaker at the Lady Davis Institute Very Distinguished Lecture Series. January 17th 2017, Montreal, Qc.
156. Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. Invited speaker at the Medical College of Wisconsin Cancer Center Hematological Malignancy & Immunotherapy Research Seminar. February 9th 2017, Milwaukee, WI.
157. MSC for GvHD: First the Commonwealth, then Japan, Next the World? Invited speaker at the Mesenchymal Stem Cell 2017 Conference sponsored by the National Center for Regenerative Medicine. August 15th 2017, Cleveland, OH.
158. MSC potency assays – An ISCT perspective. Keynote Speaker at the 8th meeting of the Asian Cellular Therapy Organization (ACTO). October 27th 2017, Tokyo, Japan.
Publications:
1. Galipeau J., Nemer M., Drouin J. Ventricular activation of the atrial natriuretic factor gene in acute myocardial infarction. New England Journal of Medicine (1988) 319:654-655
1996
2. Yang J., Galipeau J., Kozak C.A., Furie B.C., Furie B. Mouse P-selectin glycoprotein ligand-1: molecular cloning, chromosomal localization, and expression of a functional P-selectin receptor. Blood (1996) 87:4176-4186
1997
3. Galipeau J., Benaim E., Spencer T.H, Blakely R.L., Sorrentino B.P. A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs. Human Gene Therapy (1997) 8:1773-1783
4. Bunting K.D., Webb M., Giorgianni F., Galipeau J., Blakely R.L., Townsend A.J., Sorrentino B.P. Coding region-specific destabilization of mRNA transcripts attenuates expression from retroviral vectors containing class 1 aldehyde dehydrogenase cDNAs.. Human Gene Therapy (1997) 8:1531-1543
1998
5. Allay JA, Galipeau J, Blakley RL, Sorrentino BP. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells. 1998;16 Suppl 1:223-33.
6. Allay J., Person D., Galipeau J., Riberdy J.M., Ashmun R., Blakely R., Sorrentino B. In vivo selection of retrovirally transduced hematopoietic stem cells. Nature Medicine (1998) 4:1136-1143
7. Bunting K., Galipeau J., Topham D., Benaim E., Sorrentino B.P. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood (1998) 92:2269-79
1999
8. Carystinos D.C., Katabi M., Laird D.W., Galipeau J., Chan H., Alaoui-Jamali M.A., Batist G. Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. Clinical Cancer Research (1999) 5:61-68
9. Galipeau J., Li H., Paquin A., Sicilia F., Karpati G., Nalbantoglu J. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Research (1999) 59:2384-2394
10. Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP. Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. Ann N Y Acad Sci 1999 Apr 30 872 125-40; discussion 140-1
2000
11. D. E. Jaalouk, N. Eliopoulos, C. Couture, S. Mader and J. Galipeau. Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells. Human Gene Therapy (2000) 11:1837-1849
12. Sohn S. Jaitovitch-Groisman I. Benlimame N. Galipeau J. Batist G. Alaoui-Jamali MA. Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutation Research - DNA Repair. 460(1):17-28, 2000 Jun 30.
13. Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, Chiu RCJ. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. Journal of Thoracic & Cardiovascular Surgery. 120(5):999-1006, 2000 Nov.
14. Jian Mao, John Bechbberger, Darcy Lidington, Jacques Galipeau, Dale W. Laird, Christian G. Naus. Neuronal differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43. Journal of Biological Chemistry. 275(44):34407-34414, 2000 Nov 3.
15. Abdulaziz Al-Khaldi, Kevin Lachapelle and Jacques Galipeau. Endogenous ß-Galactosidase Enzyme Activity in Normal Tissues and Ischemic Myocardium – A Comparison Study with Prokaryotic ß-Galactosidase Reporter Enzyme Detection. Cardiac and Vascular Regeneration, Dec 2000;1(4):283-290
2001
16. Paquin A., Jaalouk D.E., Galipeau J. Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Human Gene Therapy. 12:13-23, 2001 Jan 1.
17. Jaitovich-Groisman I, Benlimame N, Slagle BL, Perez MH, Alpert L, Song DJ, Fotouhi-Ardakani N, Galipeau J, Alaoui-Jamali MA. Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. Journal of Biological Chemistry. 2001 Apr 27; 276(17):14124-32.
18. Caroline Trudeau, Shala Yuan, Jacques Galipeau, Naciba Benlimame, Moulay A. Alaoui-Jamali, Gerald Batist. A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells. Human Gene Therapy. 12:1665-1672, 2001 Sept 1.
19. Cécile Le Page, Oana Popescu, Pierre Génin, Jing Lion, André Paquin, Jacques Galipeau, John Hiscott. Disruption of NF-kappa B signaling and chemokine gene activation by retroviral mediated expression of IKK gamma/NEMO mutants. Virology. 2001 Aug 1;286(2):422-33.
20. M.M. Aarts, A. Corluka, E. Petroulakis, J. Guo, R. Bringhurst, J. Galipeau and J.E. Henderson. Parathyroid hormone-related protein promotes quiescence and survival of serum-deprived chondrocytes by inhibiting rRNA synthesis. J Biol Chem. 2001 Oct 12;276(41):37934-43.
21. John Stagg and Jacques Galipeau. Pseudotyped retrovectors for tumor-specific delivery of toxic suicide genes. IDrugs 2001 4(8):928-934 (Review)
22. Amir A Samani, Lucia Fallavollita, Diana E. Jaalouk, Jacques Galipeau, Pnina Brodt. Inhibition of carcinoma cell growth and metastasis by a vesicular stomatitis virus G-pseudotyped retrovector expressing type I insulin-like growth factor receptor antisense. Hum Gene Ther. 2001 Nov;12(16):1969-1977.
2002
23. Maha Katabi, Shala Yuan, Helen Chan, Jacques Galipeau, Gerald Batist. The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4. Mol Ther. 2002 Feb;5(2):170-6.
24. Nicoletta Eliopoulos, Abdulaziz Al-Khaldi, Christian M. Beausejour, Richard L. Momparler, Louise F. Momparler, Jacques Galipeau. Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther. 2002 Apr;9(7):452-62.
25. Hong Qin, Qing Shao, Heather Curtis, Jacques Galipeau, Daniel J. Belliveau, Taiqi Wang, Moulay A. Alaoui-Jamali and Dale W. Laird. Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication. J Biol Chem. 2002 Aug 9;277(32):29132-8.
26. Duguay D., Mercier F., Stagg J., Martineau D., Bramson J., Lin R., Galipeau J., Hiscott J. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res. 2002 Sep 15;62(18):5148-52
2003
27. Abdulaziz Al-Khaldi, Jacques Galipeau, Kevin Lachapelle. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Annals Thoracic Surgery 2003;75: 204–209.
28. Nicoletta Eliopoulos, Abdulaziz Al-Khaldi, Milena Crosanto, Kevin Lachapelle and Jacques Galipeau. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Therapy, 2003, mar, 10(6): 478-489
29. Abdulaziz Al-Khaldi, Nicoletta Eliopoulos, Laurence Lejeune, Daniel Martineau, Kevin Lachapelle, Jacques Galipeau. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Therapy, 2003, apr, 10(8): 621-629
30. Borhane Annabi, Ying-Ta Lee, Sandra Turcotte, Emmanuelle Naud, Richard R. Desrosiers, Nicoletta Eliopoulos, Jacques Galipeau and Richard Béliveau. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells. 2003;21(3):337-47.
31. Borhane Annabi, Sébastien Thibeault, Ying-Ta Lee, Nathalie Bousquet-Gagnon, Nicoletta Eliopoulos, Jacques Galipeau and Richard Béliveau. Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Experimental Hematology 31 (2003) 640–649
32. Julia Transfiguracion, Diana E. Jaalouk, Karim Ghani, Jacques Galipeau and Amine Kamen. Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Human Gene Therapy, 2003: 14 (12): 1139-1153
33. Caroline Rousseau, Filippa Pettersson, Marie-Claude Couture, Andre Paquin, Jacques Galipeau, Sylvie Mader, Wilson H. Miller. The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells. J Steroid Biochem Mol Biol. 2003 Jul; 86(1):1-14.
2004
34. Borhane Annabi, Emmanuelle Naud, Ying-Ta Lee, Nicoletta Eliopoulos, Jacques Galipeau. Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. Journal of Cellular Biochemistry 91:1146–1158 (2004)
35. Amir Abbas Samani, Eric Chevet, Lucia Fallavollita, Jacques Galipeau and Pnina Brodt. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Research 64, 3380-3385, May 15, 2004
36. John Stagg, Laurence Lejeune, André Paquin, Jacques Galipeau. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Human Gene Therapy 15:597–608 (June 2004)
37. Nicoletta Eliopoulos, Laurence Lejeune, Daniel Martineau and Jacques Galipeau. Human-compatible collagen matrix for prolonged and reversible systemic delivery of erythropoietin in mice from gene-modified marrow stromal cells. Molecular Therapy 10 (4): 741-748 (October 2004)
38. John Stagg, Jian Hui Wu, Nathaniel Bouganim and Jacques Galipeau. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Research 2004 Dec 15; 64(24): 8795-9.
2005
39. Sabrina R. Perri, Josephine Nalbantoglu, Borhane Annabi, Zafiro Koty, Laurence Lejeune, Moїra François, Marcos R. Di Falco, Richard Béliveau and Jacques Galipeau. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Research 2005 Sept 15, 65: 8359-8365
40. Nicoletta Eliopoulos, John Stagg, Laurence Lejeune, Sandra Pommey and Jacques Galipeau. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005 Dec 15, 106 (13): 4057-65.
2006
41. John Stagg, Sandra Pommey, Nicoletta Eliopoulos and Jacques Galipeau. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood. 2006 Mar 15;107:2570-2577.
42. Diana E. Jaalouk, Milena Crosato, Pnina Brodt and Jacques Galipeau. Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors. Virology Journal 2006, 3:27 (7 April 2006).
43. Tomas Jimenez, W. Paul Fox, Christian C.G. Naus, Jacques Galipeau, and Daniel J. Belliveau. Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy. Cell Communication and Adhesion 2006 Jan-Apr;13(1):79-92.
44. N. Eliopoulos, R.F. Gagnon, M. Francois, and J. Galipeau. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. Journal of the American Society of Nephrology 2006 Jun;17(6):1576-1584.
45. Sandra Pommey and Jacques Galipeau. [The use of mesenchymal stromal cells in oncology and cell therapy]. Bulletin du Cancer. Volume 93, Number 9, 901-7, September 2006
46. Mayya Meriane, Stéphanie Duhamel, Laurence Lejeune, Jacques Galipeau and Borhane Annabi. Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. Stem Cells 2006;24;2557-2565
47. Diana E. Jaalouk, Laurence Lejeune, Clément Couture, and Jacques Galipeau. A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells. Virol J. 2006 Nov 21;3(1):97
2007
48. Sabrina R. Perri, Daniel Martineau, Moїra François, Laurence Lejeune, and Jacques Galipeau. Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. Molecular Cancer Therapeutics 2007 Feb;6(2):441-9.
49. Moutih Rafei, Jian Hui Wu, Laurence Lejeune, Moïra François and Jacques Galipeau. A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood. 2007 Mar 1;109(5):2234-42. Epub 2006 Nov 2.
50. Currie JC., Fortier S., Sina A., Galipeau J., Cao J. & Annabi B. MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival. J Biol Chem. 2007 Mar 16;282(11):8142-9. Epub 2007 Jan 17.
51. Raphaëlle Romieu-Mourez, Moira François, Marie-Noëlle Boivin, John Stagg, Jacques Galipeau. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J. Immunol., Aug 2007; 179: 1549 - 1558.
52. Caulfield T, Ogbogu U, Nelson E, Einsiedel E, Knoppers B, McDonald M, Brunger F, Downey R, Fernando K, Galipeau J, Geransar R, Grenier G, Hyun I, Isasi R, Kardel M, Knowles L, Kucic T, Lotjonen S, Lyall D, Magnus D, Mathews DJ, Nisbet M, Nisker J, Pare G, Pattinson S, Pullman D, Rudnicki M, Williams-Jones B, Zimmerman S. Stem cell research ethics: consensus statement on emerging issues. J Obstet Gynaecol Can. 2007 Oct; 29(10):843-8.
53. Hideto Matsui, Masaru Shibata, Brain Brown, Andrea Labelle, Carol Hegadorn, Chandler Andrews, Robert P Hebbel, Jacques Galipeau, Christine Hough, David Lillicrap. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. 2007;25(10):2660-2669. Epub 2007 Jul 5.
54. Mark Blostein, Jessica Cuerquis and Jacques Galipeau. Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX. Haemophilia 2007 Nov;13(6):701-6.
55. Sabrina Perri, Borhane Annabi, Jacques Galipeau. Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton. FASEB J. 2007 Dec;21(14):3928-36. Epub 2007 Jul 10.
2008
56. Ian Copland, Kapil Sharma, Laurence Lejeune, Nicoletta Eliopoulos, Duncan Stewart, Peter Liu, Kevin Lachapelle and Jacques Galipeau. CD34 expression on murine marrow-derived mesenchymal stromal cells: impact on neovascularization. Experimental Hematology. 2008 Jan;36(1):93-103. Epub 2007 Nov 26.
57. DE Spaner, R Foley, J Galipeau and J Bramson. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene. 2008 Jan 7;27(2):208-17
58. Simon Fortier, Mohamed Touaibia, Simon Lord-Dufour, Jacques Galipeau, René Roy, Borhane Annabi. Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells. Glycobiology. 2008 Feb;18(2):195-204. Epub 2007 Dec 8.
59. Rouwayda El-Ayoubi, Nicoletta Eliopoulos, Robert DiRaddo, Jacques Galipeau, Azizeh-Mitra Yousefi. Design and fabrication of 3D porous scaffolds to facilitate cell-based gene therapy. Tissue Eng Part A. 2008 Jun;14(6):1037-48.
60. Nicoletta Eliopoulos, Moira Francois, Marie-Noelle Boivin, Daniel Martineau, and Jacques Galipeau. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Research 2008 Jun 15;68(12):4810-8.
61. Daniel L. Coutu, Jian Wui Wu, Anne Monnette, Georges-Étienne Rivard, Mark D. Blostein, Jacques Galipeau. Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. J Biol Chem. 2008 Jun 27;283(26):17991-18001. Epub 2008 Apr 30.
62. Ian B Copland, Marc E Jolicoeur, Marc-Antoine Gillis, Jessica Cuerquis, Nicoletta Eliopoulos, Borhane Annabi, Angelo Calderone, Jean-Francois Tanguay, Anique Ducharme and Jacques Galipeau. Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res. 2008 Aug 1;79(3):405-15. Epub 2008 Apr 8.
63. Claudia Penafuerte and Jacques Galipeau. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother. 2008 Aug;57(8):1197-206. Epub 2008 Jan 24.
64. Terrence Kucic, Ian B. Copland, Jessica Cuerquis, Daniel L. Coutu, Lorraine E. Chalifour, Raymonde F. Gagnon and Jacques Galipeau. Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia. Am J Physiol Renal Physiol. 2008 Aug;295(2):F488-96. Epub 2008 Jun 4.
65. Mark Blostein, Jessica Cuerquis, Sebastien Landry, Jacques Galipeau. The carboxylation efficiency of the vitamin K-dependent clotting factors: studies with factor IX. Haemophilia. 2008 Sep;14(5):1063-8. Epub 2008 Aug 1.
66. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, Forner K, Boivin MN, Doody K, Tremblay M, Annabi B and Jacques Galipeau. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008 Dec 15;112(13):4991-8. Epub 2008 Sep 23.
2009
67. Rose Geransar, Edna F. Einsiedel, Jacques Galipeau, Rosario Isasi, Lori Sheremeta and Bartha Maria Knoppers. Catalyzing umbilical cord blood research in Canada: a survey of current needs and practices of principal investigators. J Obstet Gynaecol Can. 2009 Jan;31(1):63-71.
68. Copland IB, Lord-Dufour S, Cuerquis J, Coutu DL, Annabi B, Wang E, Galipeau J. Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition. Stem Cells. 2009 Feb;27(2):467-77.
69. Philippe M. Campeau, Moutih Rafei, Moïra François, Elena Birman, Kathy Forner and Jacques Galipeau. Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72. Epub 2008 Dec 16.
70. Catherine Brunel-Guitton, Georges-Étienne Rivard, Jacques Galipeau, Nathalie Alos, Marie-Claude Miron, Roxane Therrien, Grant Mitchell, Guy Lapierre, Marie Lambert. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage? Mol Genet Metab. 2009 Feb;96(2):73-76. Epub 2008 Dec 10.
71. Moutih Rafei, Philippe M.Campeau, Jian Hui Wu, Elena Birman, Kathy Forner, Marie-Noelle Boivin, and Jacques Galipeau. Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine. J Immunol. 2009 Mar 1;182(5):2620-7.
72. Francois Mercier, Yury Monczak, Moira Francois, Jaroslav Prchal, Jacques Galipeau. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. Exp Hematol. 2009 Mar;37(3):416-420. Epub 2009 Jan 9.
73. Lord-Dufour S, Copland IB, Levros LC Jr, Post M, Das A, Khosla C, Galipeau J, Rassart E, Annabi B. Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. Stem Cells Mar 2009; 27: 489 - 497
74. Moutih Rafei, Philip Campeau, Patrick Williams, Elena Birman, Shala Yuan, Christian Young, Marie-Noelle Boivin, Kathy Forner, and Jacques Galipeau. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009 May 15;182(10):5994-6002.
75. Caulfield T, Zarzeczny A, McCormick J, Bubela T, Critchley C, Einsiedel E, Galipeau J, Harmon S, Huynh M, Hyun I, Illes J, Isasi R, Joly Y, Laurie G, Lomax G, Longstaff H, McDonald M, Murdoch C, Ogbogu U, Owen-Smith J, Pattinson S, Premji S, von Tigerstrom B, Winickoff DE. The stem cell research environment: a patchwork of patchworks. Stem Cell Rev Rep. 2009 Jun;5(2):82-8. Epub 2009 May 27.
76. Raphaëlle Romieu-Mourez, Moïra François, Marie-Noëlle Boivin, David E. Spaner and Jacques Galipeau. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol. 2009 Jun 15;182(12):7963-73.
77. Ni Wang, Lucia Fallavollita; Long Nguyen; Julia V Burnier; Moutih Rafei; Jacques Galipeau; Shoshana Yakar; Pnina Brodt. Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol Ther. 2009 Jul;17(7):1241-9. Epub 2009 Apr 14.
78. Moutih Rafei, Yamina A. Berchiche, Elena Birman, Marie-Noelle Boivin, Nikolaus Heveker and Jacques Galipeau. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J Immunol. 2009 Aug 1;183(3):1759-66. Epub 2009 Jul 10.
79. Moutih Rafei, Jeremy Hsieh, Simone Zehntner, MengYang Li, Kathy Forner, Elena Birman, and Jacques Galipeau. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med. 2009 Sep;15(9):1038-1045. Epub 2009 Aug 9.
80. Almadi M, Ghali PM, Constantin A, Galipeau J, Szilagyi A. Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review. Can J Gastroenterol. 2009 Sep;23(9):625-31.
81. Moïra François, Raphaëlle Romieu-Mourez, Sophie Martineau, Marie-Noëlle Boivin, Jonathan L. Bramson, Jacques Galipeau. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood. 2009 Sep 24;114(13):2632-8. Epub 2009 Aug 4.
82. Moutih Rafei, Elena Birman, Kathy Forner, and Jacques Galipeau. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther. 2009 Oct;17(10):1799-803. Epub 2009 Jul 14.
83. Philippe M. Campeau, Moutih Rafei, Marie-Noëlle Boivin, Marie Lambert, Ying Sun, Gregory A. Grabowski and Jacques Galipeau. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009 Oct 8;114(15):3181-90. Epub 2009 Jul 8.
84. Daniel L.Coutu, Azizeh-Mitra Yousefi, Jacques Galipeau. Three-dimensional porous scaffolds at the crossroads of tissue engineering and cell-based gene therapy. J Cell Biochem. 2009 Oct 15;108(3):537-46.
85. Moutih Rafei, Jacques Galipeau. GIFT15 fusokine to foil immunity's follies. Immunotherapy. 2009 Nov:1(6):913-915
86. Penafuerte C, Bautista-Lopez N, Mohamed-Rachid B, Routy JP, Galipeau J. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res. 2009 Dec 1;69(23):9020-8. Epub 2009 Nov 17.
87. van Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, Rey-Parra GJ, Galipeau J, Haromy A, Eaton F, Chen M, Hashimoto K, Abley D, Korbutt G, Archer SL, Thébaud B. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1131-1142. Epub 2009 Aug 27.
2010
88. Bouchentouf M, Paradis P, Forner KA, Cuerquis J, Boivin MN, Zheng J, Boulassel MR, Routy JP, Schiffrin EL, Galipeau J. Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant. 2010;19(4):369-86. Epub 2009 Dec 18
89. Moutih Rafei, Jacques Galipeau. [A chimeric cytokine to help autoimmune diseases]. Med Sci (Paris). 2010 Feb;26(2):137-9.
90. Monica Taljaard, Michael R. Ward, Michael J. B. Kutryk, David W. Courtman, Nancy J. Camack, Shaun G. Goodman, Thomas G. Parker, Alexander J. Dick, Jacques Galipeau, and Duncan J. Stewart. Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am Heart J. 2010 Mar;159(3):354-360.
91. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A; MSCT Study Group. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler. 2010 Apr;16(4):503-10. Epub 2010 Jan 19
92. Patrick Williams, Moutih Rafei, Jennifer Raven, Shala Yuan, Jessica Cuerquis, Kathy Ann Forner, Elena Birman, Jacques Galipeau. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther. 2010 Jul;18(7):1293-301. Epub 2010 Apr 13.
93. Darlington PJ, Boivin MN, Renoux C, François M, Galipeau J, Freedman MS, Atkins HL, Cohen JA, Solchaga L, Bar-Or A. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol. 2010 Oct;68(4):540-5.
94. Raphaëlle Romieu-Mourez, Amanda Abate, Moïra François, Marie-Noëlle Boivin, Elena Birman, Kathy Forner, Christian Young, Jeffrey A. Medin and Jacques Galipeau. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. Cancer Res. 2010 Oct 15;70(20):7742-7. Epub 2010 Oct 5.
95. Moutih Rafei and Jacques Galipeau. A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseases. Crit Rev Immunol. 2010;30(5):449-461.
96. Bouchentouf M.; Forner KA; Cuerquis J; Michaud V; Zheng J; Paradis P; Boulassel MR; Routy J.P.; Schiffrin EL and Galipeau J. Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and α4β7 integrin expression by NK cells. J Immunol. 2010 Dec 1;185(11):7014-7025. Epub 2010 Oct 22.
97. Patrick Williams, Manaf Bouchentouf, Moutih Rafei, Raphaëlle Romieu-Mourez, Hsiang Chuan Hsieh, Marie-Noëlle Boivin, Shala Yuan, Kathy Ann Forner, Elena Birman, Jacques Galipeau. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity. J Immunol. 2010 Dec 15;185(12):7358-66. Epub 2010 Nov 12.
2011
98. Patrick Williams, Jacques Galipeau. GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. J Intern Med. 2011 Jan;269(1):74-84. doi: 10.1111/j.1365-2796.2010.02314.x.
99. Daniel L.Coutu, Jessica Cuerquis, Rouwayda El Ayoubi, Kathy-Ann Forner, Ranjan Roy, Moira François, Alex Hyatt, May Griffith, David Lillicrap, Azizeh-Mitra Yousefi, Mark D. Blostein & Jacques Galipeau. Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B. Biomaterials. 2011 Jan;32(1):295-305.
100. Bouchentouf M, Forner K, Cuerquis J, Boulassel MR, Routy JP, Waller EK, Quyyumi AA, Paradis P, Schiffrin EL, and Galipeau J. A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease. Cell Transplant. 2011;20(9):1431-43. Epub 2011 Feb 3.
101. Jacques Corcos, Oleg Loutochin, Lysanne Campeau, Nicoletta Eliopoulos, Manaf Bouchentouf, Bertil Blok, Jacques Galipeau. Bone marrow mesenchymal stromal cell therapy for external urethral sphincter restoration in a rat model of stress urinary incontinence. Neurourol Urodyn. 2011 Mar;30(3):447-55. Epub 2010 Nov 2.
102. Patrick Williams and Jacques Galipeau. GM-CSF-based fusion cytokines as ligands for immune modulation. J Immunol. 2011 May 15;186(10):5527-32.
103. Claudia Penafuerte, Norma Bautista-Lopez, Manaf Bouchentouf, Elena Birman, Kathy Forner, Jacques Galipeau. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol. 2011 Jun 15;186(12):6933-44. Epub 2011 May 6.
104. Daniel L. Coutu, Moira Francois, Jacques Galipeau. Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood. 2011 Jun 23;117(25):6801-12. Epub 2011 Apr 28.
105. Rafei M, Hardy MP, Williams P, Vanegas JR, Forner KA, Dulude G, Labrecque N, Galipeau J, Perreault C. Development and function of innate polyclonal TCRalphabeta+ CD8+ thymocytes. J Immunol. 2011 Sep 15;187(6):3133-44. Epub 2011 Aug 15.
106. Rafei M, Deng J, Boivin MN, Williams P, Matulis SM, Yuan S, Birman E, Forner K, Yuan L, Castellino C, Boise LH, Macdonald TJ, Galipeau J. A MCP1 fusokine with CCR2-specific tumoricidal activity. Mol Cancer. 2011 Sep 24;10(1):121.
107. Daniel L.Coutu & Jacques Galipeau. Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (Albany NY). 2011 Oct;3(10):920-33.
108. Ian B. Copland and Jacques Galipeau. Death and inflammation following somatic cell transplantation. Semin Immunopathol. 2011 Nov;33(6):535-50. Epub 2011 May 1.
109. Bouchentouf M, Williams P, Forner KA, Cuerquis J, Michaud V, Paradis P, Schiffrin EL and Galipeau J. Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. Cytokine. 2011 Dec;56(3):732-8. Epub 2011 Oct 17.
2012
110. François M, Romieu-Mourez R, Li M, Galipeau J. Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2,3-Dioxygenase and Bystander M2 Macrophage Differentiation. Mol Ther. 2012 Jan;20(1):187-95. doi: 10.1038/mt.2011.189. Epub 2011 Sep 20.
111. Romieu-Mourez R, Coutu DL, Galipeau J. The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies. Front Biosci (Elite Ed). 2012 Jan 1;4:824-37.
112. Sensebé L, Tarte K, Galipeau J, Krampera M, Martin I, Phinney DG, Shi Y. Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell. 2012 Jan 6;10(1):9-10.
113. Lu Y, Giver CR, Sharma A, Li JM, Darlak KA, Owens LM, Roback JD, Galipeau J, Waller EK. Interferon-gamma and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood. 2012 Jan 26;119(4):1075-85. Epub 2011 Nov 30.
114. François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy. 2012 Feb;14(2):147-52. Epub 2011 Oct 27.
115. Penafuerte C, Galipeau J. FIST, a sword and shield fusokine for cancer immunotherapy.. Oncoimmunology. 2012 Mar 1;1(2):224-226.
116. Penafuerte C, Ng S, Bautista-Lopez N, Birman E, Forner K, Galipeau J. B Effector Cells activated by a chimeric protein consisting of IL-2 and the Ectodomain of Transforming Growth Factor beta Receptor II Induce Potent Anti-tumor Immunity. Cancer Res. 2012 Mar 1;72(5):1210-20. Epub 2012 Jan 12.
117. Deng J, Galipeau J. Reprogramming of B Cells into Regulatory Cells with Engineered Fusokines. Infect Disord Drug Targets. 2012 Jun 1;12(3):248-54
118. Hsieh J, Williams P, Rafei M, Birman E, Cuerquis J, Yuan S, Wu J, Galipeau J. Inducible IL10(+) Suppressor B Cells Inhibit CNS Inflammation and T Helper 17 Polarization. Mol Ther. 2012 Sep;20(9):1767-77. doi: 10.1038/mt.2012.127. Epub 2012 Jul 3.
119. François M, Galipeau J. New insights on translational development of mesenchymal stromal cells for suppressor therapy. J Cell Physiol. 2012 Nov;227(11):3535-8. doi: 10.1002/jcp.24081.
120. François M, Birman E, Forner KA, Gaboury L, Galipeau J. Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. Cytotherapy. 2012 Nov;14(10):1164-70. doi: 10.3109/14653249.2012.684378. Epub 2012 May 10.
2013
121. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013 Jan;15(1):2-8. doi: 10.1016/j.jcyt.2012.10.002.
122. Bautista-López NL, Morillo CA, López-Jaramillo P, Quiroz R, Luengas C, Silva SY, Galipeau J, Lalu MM, Schulz R. Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. Am Heart J. 2013 Apr;165(4):558-66. doi: 10.1016/j.ahj.2013.01.001. Epub 2013 Feb 15.
123. Galipeau, J. Concerns arising from MSC retrieval from cryostorage and effect on immune suppressive function and pharmaceutical usage in clinical trials. ISBT Science Series. 2013 May; 8: 100–101. doi: 10.1111/voxs.12022
124. Stagg J, Galipeau J. Mechanisms of Immune Modulation By Mesenchymal Stromal Cells and Clinical Translation. Curr Mol Med. 2013 Jun 1;13(5):856-67.
125. Phinney DG, Galipeau J, Krampera M, Martin I, Shi Y, Sensebe L. MSCs: science and trials. Nat Med. 2013 Jul;19(7):812. doi: 10.1038/nm.3220. No abstract available.
126. Li P, Yuan S, Galipeau J. A Fusion Cytokine Coupling GMCSF to IL9 Induces Heterologous Receptor Clustering and STAT1 Hyperactivation through JAK2 Promiscuity. PLoS One. 2013 Jul 1;8(7):e69405. doi: 10.1371/journal.pone.0069405. Print 2013.
127. Forghani P, Harris W, Giver CR, Mirshafiey A, Galipeau J, Waller EK. Properties of Immature Myeloid Progenitors with Nitric-Oxide-Dependent Immunosuppressive Activity Isolated from Bone Marrow of Tumor-Free Mice. PLoS One. 2013 Jul 2;8(7):e64837. Print 2013.
128. Krampera M*, Galipeau J*, Shi Y, Tarte K, Sensebe L; On behalf of the MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013 Sep;15(9):1054-61. doi: 10.1016/j.jcyt.2013.02.010. Epub 2013 Apr 17.
129. Copland IB, Garcia MA, Waller EK, Roback JD, Galipeau J. The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials. 2013 Oct;34(32):7840-50. doi: 10.1016/j.biomaterials.2013.06.050. Epub 2013 Jul 24.
130. Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, El Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013 Nov 1;119(21):3784-7. doi: 10.1002/cncr.28253. Epub 2013 Aug 6.
131. Raghavan Chinnadurai, Edmund K. Waller, Jacques Galipeau, and Ajay K. Nooka. From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases. Biomed Res Int. 2013;2013:929842. Epub 2013 Nov 19. Review.
2014
132. Chinnadurai R, Copland IB, Patel S and Galipeau J. IDO-Independent Suppression of T Cell Effector Function by IFN-γ-Licensed Human Mesenchymal Stromal Cells. J Immunol. 2014 Feb 15;192(4):1491-501. doi: 10.4049/jimmunol.1301828. Epub 2014 Jan 8.
133. Chinnadurai R, Garcia MA, Sakurai Y, Lam WA, Kirk AD, Galipeau J, Copland IB. Actin Cytoskeletal Disruption following Cryopreservation Alters the Biodistribution of Human Mesenchymal Stromal Cells In Vivo. Stem Cell Reports. 2014 Jun 6;3(1):60-72.
134. Jiusheng Deng, Shala Yuan, Andrea Pennati, Jordan Murphy, Jian Hui Wu, David Lawson, Jacques Galipeau. Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T cell response. Cancer Res. 2014 Aug 1;74(15):4133-44. doi: 10.1158/0008-5472.CAN-14-0708. Epub 2014 Jun 17.
135. Andrea Pennati, Jiusheng Deng and Jacques Galipeau. Maltose-Binding Protein Fusion Allows for High Level Bacterial Expression and Purification of Bioactive Mammalian Cytokine Derivatives. PLoS One. 2014 Sep 8;9(9):e106724. doi: 10.1371/journal.pone.0106724. eCollection 2014.
136. Kamalika Mojumdar, Feng Liang, Christian Giordano, Christian Lemaire, Gawiyou Danialou, Tatsuma Okazaki, Johanne Bourdon, Moutih Rafei, Jacques Galipeau, Maziar Divangahi, Basil J. Petrof. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2. EMBO Mol Med. 2014 Oct 13;6(11):1476-92. doi: 10.15252/emmm.201403967.
137. Coutu DL, Mahfouz W, Loutochin O, Galipeau J, Corcos J. Tissue engineering of rat bladder using marrow-derived mesenchymal stem cells and bladder acellular matrix. PLoS One. 2014 Dec 1;9(12):e111966. doi: 10.1371/journal.pone.0111966. eCollection 2014.
138. Jiusheng Deng, Jacques Galipeau. B cells for cancer immunotherapy. Oncoimmunology. 2014 Dec 15;3(10):e955702. eCollection 2014 Nov
2015
139. Spencer Ng, Jacques Galipeau. Concise Review: Engineering the Fusion of Cytokines for the Modulation of Immune Cellular Responses in Cancer and Autoimmune Disorders. Stem Cells Transl Med. 2015 Jan;4(1):66-73. doi: 10.5966/sctm.2014-0145. Epub 2014 Nov 12.
140. Jacques Galipeau and Mauro Krampera. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy. 2015 Feb;17(2):125-7. doi: 10.1016/j.jcyt.2014.12.008.
141. Patel SR, Copland IB, Garcia MA, Metz R, Galipeau J. Human mesenchymal stromal cells suppress T-cell proliferation independent of heme oxygenase-1. Cytotherapy. 2015 Apr;17(4):382-91. doi: 10.1016/j.jcyt.2014.11.010. Epub 2015 Jan 14.
142. Raghavan Chinnadurai, Spencer Ng, Vijayakumar Velu, Jacques Galipeau. Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease. World J Gastroenterol. 2015 Apr 28;21(16):4779-4787.
143. Jakob Habib, Jiusheng Deng, Neil Lava, William Tyor, Jacques Galipeau. Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients. J Mult Scler (Foster City). 2015 May;2(2). pii: 1000139.
144. Hsieh J, Ng S, Bosinger S, Wu JH, Tharp GK, Garcia A, Hossain MS, Yuan S, Waller EK, Galipeau J. A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. Clin Transl Immunology. 2015 May 8;4(5):e37. doi: 10.1038/cti.2015.8. eCollection 2015 May.
145. Ian Copland, Muna Qayed, Marco A Garcia, Jacques Galipeau, Edmund K Waller. Bone marrow Mesenchymal Stromal Cells from patients with acute and chronic GVHD deploy normal phenotype, differentiation plasticity, and immune-suppressive activity. Biol Blood Marrow Transplant. 2015 May;21(5):934-940. doi: 10.1016/j.bbmt.2015.01.014. Epub 2015 Feb 3.
146. Raghavan Chinnadurai, Ian B Copland, Spencer Ng, Marco Garcia, Mahadev Prasad, Dalia Arafat, Greg Gibson, Subra Kugathasan, Jacques Galipeau. Mesenchymal stromal cells derived from Crohn's patients deploy indoleamine 2,3-dioxygenase mediated immune suppression, independent of autophagy. Mol Ther. 2015 Jul;23(7):1248-61. doi: 10.1038/mt.2015.67. Epub 2015 Apr 22.
147. Feng H, Zhang H, Deng J, Wang L, He Y, Wang S, Seyedtabaei R, Wang Q, Liu L, Galipeau J, Compans RW, Wang BZ. Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. Sci Rep. 2015 Jul 7;5:11856. doi: 10.1038/srep11856.
148. Granton J, Langleben D, Kutryk MJ, Camack N, Galipeau J, Courtman D, Stewart DJ. Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: the PHACeT Trial. Circ Res. 2015 Sep 11;117(7):645-54. doi: 10.1161/CIRCRESAHA.114.305951. Epub 2015 Jul 20.
149. Elizabeth O. Stenger, Lakshmanan Krishnamurti, and Jacques Galipeau. Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. BMC Immunol. 2015 Dec 16;16:74. doi: 10.1186/s12865-015-0135-7.
2016
150. Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MBC, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Prockop DJ, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ and Sensebe L. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016 Feb;18(2):151-9. doi: 10.1016/j.jcyt.2015.11.008. Epub 2015 Dec 23.
151. Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget. 2016 Mar 31. doi: 10.18632/oncotarget.8513. [Epub ahead of print]
152. Jiusheng Deng, Andrea Pennati, Yuanqiang Wu, Jonathon B. Cohen, Spencer Ng, Jian Hui Wu, Christopher R. Flowers, and Jacques Galipeau. GIFT4 Fusokine Converts Leukemic B Cells into Anti-CLL Effectors. J Transl Med. 2016 Apr 27;14(1):106. doi: 10.1186/s12967-016-0865-1.
153. Scott T Robinson, Alison M Douglas, Tatiana Chadid, Katie Kuo, Ajai Rajabalan, Haiyan Li, Ian B Copland, Thomas H Barker, Jacques Galipeau, Luke Brewster. A Novel Platelet Lysate Hydrogel for Endothelial Cell and Mesenchymal Stem Cell-Directed Neovascularization. Acta Biomater. 2016 May;36:86-98. doi: 10.1016/j.actbio.2016.03.002. Epub 2016 Mar 4.
154. Raghavan Chinnadurai, Ian B Copland, Marco A Garcia, Christopher Petersen, Christopher Lewis, Edmund K. Waller, Allan Kirk, Jacques Galipeau. Cryopreserved MSCs are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells. 2016 Sep;34(9):2429-42. doi: 10.1002/stem.2415. Epub 2016 Jul 4.
155. Tanvi Dhere, Ian Copland, Marco Garcia, KY Chiang, Raghavan Chinnadurai, Mahadev Prasad, Jacques Galipeau and Subra Kugathasan. Randomised clinical trial: safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses. Aliment Pharmacol Ther. 2016 Sep;44(5):471-81. doi: 10.1111/apt.13717. Epub 2016 Jul 7.
156. Spencer Ng, Jiusheng Deng, Raghavan Chinnadurai, Shala Yuan, Andrea Pennati, Jacques Galipeau. Stimulation of natural killer cell-mediated tumor immunity by an IL-15/TGF-ß neutralizing fusion protein. Cancer Res. 2016 Oct 1;76(19):5683-5695.
157. Galipeau J. Letter to the Editor - Response to "Function of Cryopreserved MSCs with and without IFN-γ pre-licensing is Context Dependent" by Ankrum et al. Stem Cells. 2016 Oct 19. doi: 10.1002/stem.2526.
158. Andrea Pennati, Spencer Ng, Yuanqiang Wu, Jordan R. Murphy, Jiusheng Deng, Jennifer L. Blanchfield, Brian Evavold and Jacques Galipeau. Regulatory B cells induce formation of IL-10 expressing T cells in mice with autoimmune neuroinflammation. J Neurosci. 2016 Dec 14;36(50):12598-12610.
2017
159. Jiusheng Deng, Andrea Pennati, Shala Yuan, Jian Hui Wu, Krishnendu Roy, Edmund Waller, Jacques Galipeau. GM-CSF and IL-4 fusion cytokine Induces B Cell-dependent Hematopoietic Regeneration. Mol Ther. 2017 Feb 1;25(2):416-426. doi: 10.1016/j.ymthe.2016.11.013
160. Raghavan Chinnadurai, Devi Rajan, Spencer Ng, Kenneth McCullough, Dalia Arafat, Edmund K Waller, Larry J Anderson, Greg Gibson, Jacques Galipeau. Immune dysfunctionality of replicative senescent Mesenchymal Stromal Cells are corrected by IFNγ priming. Blood Adv. 2017 Apr 25;1(11):628-643. doi: 10.1182/bloodadvances.2017006205.
161. Elizabeth O. Stenger, Raghavan Chinnadurai, Shala Yuan, Marco Garcia, Dalia Arafat, Greg Gibson, Lakshmanan Krishnamurti, and Jacques Galipeau. Bone Marrow Derived Mesenchymal Stromal Cells From Sickle Cell Disease Patients Display Intact Functionality. Biol Blood Marrow Transplant. 2017 May;23(5):736-745. doi: 10.1016/j.bbmt.2017.01.081. Epub 2017 Jan 26.
162. Conklin LS, Hanley PJ, Galipeau J, Barrett J, Bollard CM. Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience. Cytotherapy. 2017 Jun;19(6):655-667. doi: 10.1016/j.jcyt.2017.03.006. Epub 2017 Apr 19. Review.
163. Lewis, Christopher Holly, Chinnadurai, Raghavan; Bosinger, Steven E., Galipeau, Jacques. The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells. Oncotarget. 2017 Aug 10;8(54):91914-91927. doi: 10.18632/oncotarget.20166. eCollection 2017 Nov 3.
164. Rajan D, Chinnadurai R, Keefe EO, Boyoglu-Barnum S, Todd SO, Hartert TV, Galipeau J, Anderson LJ. Protective role of Indoleamine 2,3 dioxygenase in Respiratory Syncytial Virus associated immune response in airway epithelial cells. Virology. 2017 Dec;512:144-150. doi: 10.1016/j.virol.2017.09.007. Epub 2017 Sep 28.
2018
165. Naskou MC, Norton NA, Copland IB, Galipeau J, Peroni JF. Innate immune responses of equine monocytes cultured in equine platelet lysate. Vet Immunol Immunopathol. 2018 Jan;195:65-71. doi: 10.1016/j.vetimm.2017.11.005. Epub 2017 Nov 16.
166. Andrea Pennati, Seneshaw Asress, Jonathan D. Glass, and Jacques Galipeau. Adoptive transfer of IL-10+ regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model. Cell Mol Immunol. 2018 Jan 8. doi: 10.1038/cmi.2017.152. [Epub ahead of print]
167. Raghavan Chinnadurai, Devi Rajan, Muna Qayed, Dalia Arafat, Marco Garcia, Yifei Liu, Subra Kugathasan, Larry J Anderson, Greg Gibson, Jacques Galipeau. Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. Cell Rep. 2018 Feb 27;22(9):2504-2517. doi: 10.1016/j.celrep.2018.02.013.
Manuscripts in review
1. Tatiana Chadid, Andrew Morris, Scott Robinson, Katie Kuo, Haiyan Li, Mason Griffin, Ian Copland, Jacques Galipeau and Luke P. Brewster. In Vitro Characterization of Bone Marrow and Adipose Tissue-derived Human Diabetic Mesenchymal Stem Cells from Patients with Peripheral Arterial Disease. Submitted 2017
2. Doan C. Nguyen, Shuya Kyu, Jessica R. Williams, So-Hee Hong, Igor Albizua-Santin, Jacques Galipeau, Kuang-Yueh Chiang, Edmund K. Waller, Swetha Garimalla, Gregory Gibon, James Roberson, Frances E. Lund, John E. Bradley, Troy D. Randall, Inaki Sanz, F. Eun-Hyung Lee. Long-term in vitro Cell-free Human Plasma Cell Survival System. Submitted 2017
3. Holly C. Lewis, Doan C. Nguyen, Vivien Warren, Haopeng Xiao, Haydn Thomas Kissick, Ronghu Wu, Jacques Galipeau, F. Eun-Hyung Lee. Exosomes from Bone Marrow-derived Mesenchymal Stromal Cells Support Ex Vivo Survival of Human Antibody Secreting Cells. Submitted 2017
4. Galipeau J. and Sensebe L. Perspective: Mesenchymal Stromal Cells – addressing the dissonance of pre-clinical science and clinical development. Submitted 2018
5. Ivan Martin, Jacques Galipeau, Charles Kessler, Katarina Le Blanc, Francesco Dazzi. Challenges in developing mesenchymal stem cell-based clinical treatments. Submitted 2018
Book Chapters and monographs:
1. Galipeau, J., Massie B., Langelier Y., Piché A., Tanguay R.M. La thérapie génique: D’un enthousiasme excessif à un optimisme prudent. Invited contribution to a series on genomics published on July 29th, 2000 in Le Devoir (a French language Montreal newspaper).
2. Eliopoulos N. and Galipeau J. Green fluorescent protein in retroviral vector constructs as marker and reporter of gene expression for cell and gene therapy applications. Methods Mol Biol. 2002; 183:353-71.
3. Spencer H. T & Galipeau J. Gene Therapy for the Treatment of Cancer. Chapter 27 in the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Edited by: W. D. Figg and H. L. McLeod © Humana Press Inc., Totowa, NJ as part of the NCI Cancer Drug Discovery Series 2002
4. John Stagg & Jacques Galipeau. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handbook of Experimental Pharmacology: Bone marrow-derived Progenitors. Edited by K. Kauser and A.M. Zeiher. Ed. Springer (Berlin, Germany). Handb Exp Pharmacol. 2007;(180):45-66.
5. Moira Francois and Jacques Galipeau. Mesenchymal Stromal Cells: An Emerging Cell-Based Pharmaceutical. Experimental and Applied Immunotherapy, Pages: 127-148 DOI: 10.1007/978-1-60761-980-2_6 Published: 2011, J. Medin and D. Fowler (eds.).
6. Daniel L. Coutu, Moïra François & Jacques Galipeau. Mesenchymal Stem Cells and Tissue Repair. Regenerative Therapy Using Blood-Derived Stem Cells. Edited by David S. Allan and Dirk Strunk Book Series: Stem Cell Biology and Regenerative Medicine Pages: 35-51 DOI: 10.1007/978-1-61779-471-1_4 Published: 2012
7. Coutu DL, Galipeau J. (2013) Molecular and endocrine mechanisms underlying the stem cell theory of aging. In: Adult Stem Cells, Turksen K. (Ed.). Pages: 389-417 DOI: 10.1007/978-1-4614-9569-7
8. Raphaëlle Romieu-Mourez and Jacques Galipeau. Mesenchymal Stromal Cells as Effective Tumor Antigen-Presenting Cells in Cancer Therapeutics. In: Stem Cell Therapeutics for Cancer. Published Online: 9 AUG 2013 DOI: 10.1002/9781118660423.ch10
9. Raghavan Chinnadurai, Jacques Galipeau. Defining the Immune Plasticity Mesenchymal Stromal Cells as a Surrogate Measure of Suppressive Potency. Mini Review published in Inflammation and Regeneration. 2014; 34(4): 168-175
10. Lewis C and Galipeau J. Mesenchymal stromal cells for the treatment of autoimmune disease. The Biology and Therapeutic Application of Mesenchymal Cells, Pages 794-813. Edited by Kerry Atkinson. ISBN 9781118907375. Publisher John Wiley & Sons, 2016
11. Qayed M and Galipeau J. Allogeneic Versus Autologous MSCs and Donor to Donor Variability. In Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption. Viswanathan S, Hematti P, editors. First ed. Academic Press; 2017 Chapter 4: 97-120. ISBN: 978-0-12-802826-1
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- university of wisconsin school rankings
- curriculum vitae template word document
- curriculum vitae finance manager sample
- university of wisconsin madison graduation
- university of wisconsin academic calendar
- university of wisconsin 2020 2021 calendar
- curriculum vitae format in word
- curriculum vitae sample doc
- curriculum vitae sample pdf
- curriculum vitae samples for teachers
- curriculum vitae template free download
- curriculum vitae template word download